View Filing Data

Document Entity Information - USD ($)	12 Months Ended
Document Entity Information - USD ($)	Dec. 31, 2013	Feb. 25, 2014	Jun. 28, 2013
Document Entity Information [Abstract]
Entity Registrant Name	BioScrip, Inc.
Entity Central Index Key	0001014739
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		68,187,087
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 776,433,834

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2013	Dec. 31, 2012
Current assets
Cash and cash equivalents	$ 1,001	$ 62,101
Receivables, less allowance for doubtful accounts of $19,213 and $22,212 at December 31, 2013 and December 31, 2012, respectively	187,301	129,103
Inventory	34,341	34,034
Prepaid expenses and other current assets	14,313	10,189
Total current assets	236,956	235,427
Property and equipment, net	41,612	23,721
Goodwill	605,121	350,810
Intangible assets, net	32,224	17,446
Deferred financing costs	17,184	2,877
Investments in and advances to unconsolidated affiliate	0	10,042
Other non-current assets	3,761	2,053
Total assets	936,858	642,376
Current liabilities
Current portion of long-term debt	60,257	953
Accounts payable	64,342	34,438
Claims payable	2,547	7,411
Amounts due to plan sponsors	5,090	18,173
Accrued interest	2,173	5,803
Accrued expenses and other current liabilities	39,897	41,491
Total current liabilities	174,306	108,269
Long-term debt, net of current portion	375,322	225,426
Deferred taxes	15,107	10,291
Other non-current liabilities	17,540	4,981
Total liabilities	582,275	348,967
Stockholders' equity
Preferred stock, $.0001 par value; 5,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $.0001 par value; 125,000,000 shares authorized; 70,711,439 and 59,600,713 shares issued and 68,128,919 and 57,026,957 shares outstanding as of December 31, 2013 and 2012, respectively	7	6
Treasury stock, 2,582,520 shares at cost	(10,311)	(10,311)
Additional paid-in capital	519,625	388,798
Accumulated deficit	(154,738)	(85,084)
Total stockholders' equity	354,583	293,409
Total liabilities and stockholders' equity	$ 936,858	$ 642,376

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2013	Dec. 31, 2012
Condensed Consolidate Balance Sheets Parenthetical [Abstract]
Allowance for Doubtful Accounts Receivable, Current	$ 19,213	$ 22,212
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	125,000,000	125,000,000
Common Stock, Shares, Issued	70,711,439	59,600,713
Common Stock, Shares, Outstanding	68,128,919	57,026,957
Treasury Stock, Shares	2,582,520	2,582,520

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Statement [Abstract]
Product revenue	$ 675,684	$ 471,506	$ 365,526
Service revenue	166,511	191,131	188,980
Total revenue	842,195	662,637	554,506
Cost of product revenue	466,155	325,271	238,072
Cost of service revenue	104,226	112,406	101,019
Total cost of revenue	570,381	437,677	339,091
Gross profit	271,814	224,960	215,415
Selling, general and administrative expenses	233,038	184,491	167,136
Change in fair value of contingent consideration	(5,786)	0	0
Bad debt expense	20,963	14,035	11,441
Acquisition and integration expenses	16,130	4,046	0
Restructuring and other expenses	7,771	5,143	7,909
Amortization of intangibles	6,671	3,957	3,376
Income (loss) from operations	(6,973)	13,288	25,553
Interest expense, net	28,197	26,067	25,542
Loss on extinguishment of debt	15,898	0	0
Income (loss) from continuing operations, before income taxes	(51,068)	(12,779)	11
Income tax provision (benefit)	2,538	(4,439)	435
Loss from continuing operations, net of income taxes	(53,606)	(8,340)	(424)
Less: Income (loss) from discontinued operations, net of income taxes	(16,048)	73,047	8,296
Net income (loss)	$ (69,654)	$ 64,707	$ 7,872
Income (loss) per common share
Loss from continuing operations, basic and diluted (in dollars per share)	$ (0.83)	$ (0.15)	$ (0.01)
Income (loss) from discontinued operations, basic and diluted (in dollars per share)	(0.25)	1.30	0.15
Income (loss), basic and diluted (in dollars per share)	$ (1.08)	$ 1.15	$ 0.14
Weighted average common shares outstanding
Weighted average common shares outstanding, basic and diluted (in shares)	64,560	56,239	54,505

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Treasury Stock	Additional Paid-in Capital	Retained Earnings
Balance at Dec. 31, 2010	$ 200,101	$ 6	$ (10,496)	$ 368,254	$ (157,663)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of employee stock compensation plans	3,198	0	0	3,198	0
Surrender of stock to satisfy minimum tax withholding	(189)	0	(189)	0	0
Issuance of treasury stock for restricted stock vesting	0	0	224	(224)	0
Compensation under employee stock compensation plan	4,297	0	0	4,297	0
Net income (loss)	7,872				7,872
Net proceeds of public stock offering	0
Balance at Dec. 31, 2011	215,279	6	(10,461)	375,525	(149,791)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of employee stock compensation plans	8,611	0	0	8,611	0
Surrender of stock to satisfy minimum tax withholding	(174)	0	(174)	0	0
Issuance of treasury stock for restricted stock vesting	0		324	(324)	0
Compensation under employee stock compensation plan	4,986	0	0	4,986	0
Net income (loss)	64,707				64,707
Net proceeds of public stock offering	0
Balance at Dec. 31, 2012	293,409	6	(10,311)	388,798	(85,084)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of employee stock compensation plans	2,549	0	0	2,549	0
Compensation under employee stock compensation plan	9,498	0	0	9,498	0
Net income (loss)	(69,654)				(69,654)
Net proceeds of public stock offering	118,382	1	0	118,381	0
Exercise of warrants	399	0	0	399	0
Balance at Dec. 31, 2013	$ 354,583	$ 7	$ (10,311)	$ 519,625	$ (154,738)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:
Net income	$ (69,654)	$ 64,707	$ 7,872
Less: Income (loss) from discontinued operations, net of income taxes	(16,048)	73,047	8,296
Loss from continuing operations, net of income taxes	(53,606)	(8,340)	(424)
Adjustments to reconcile net loss from continuing operations to net cash provided by (used in) operating activities:
Depreciation	13,555	8,513	6,591
Amortization of intangibles	6,671	3,957	3,376
Amortization of deferred financing costs	2,259	1,261	1,055
Change in fair value of contingent consideration	(5,786)	0	0
Change in deferred income tax	4,816	(4)	1,153
Compensation under stock-based compensation plans	9,450	6,122	4,467
Loss on disposal of fixed assets	0	156	201
Loss on extinguishment of debt	15,898	0	0
Equity in earnings of unconsolidated affiliate	675	0	0
Changes in assets and liabilities, net of acquired businesses:
Receivables, net of bad debt expense	(31,861)	101,230	(31,690)
Inventory	4,939	(15,249)	(2,497)
Prepaid expenses and other assets	(420)	3,726	11,211
Accounts payable	22,136	(48,200)	(1,659)
Claims payable	(4,864)	(4,354)	8,729
Amounts due to plan sponsors	(13,084)	(7,046)	5,437
Accrued interest	(3,627)	(22)	59
Accrued expenses and other liabilities	(5,656)	8,112	(2,945)
Net cash provided by (used in) operating activities from continuing operations	(38,505)	49,862	3,064
Net cash provided by (used in) operating activities from discontinued operations	(16,048)	(22,978)	23,905
Net cash provided by (used in) operating activities	(54,553)	26,884	26,969
Cash flows from investing activities:
Purchases of property and equipment, net	(25,626)	(10,986)	(7,853)
Cash consideration paid for acquisitions, net of cash acquired	(282,998)	(43,046)	(463)
Cash consideration paid for unconsolidated affiliate, net of cash acquired	(8,617)	0	0
Cash advances to unconsolidated affiliate	(2,363)	0	0
Cash consideration paid to DS Pharmacy	0	(2,935)	0
Cash consideration paid for unconsolidated affiliate, net of cash acquired	0	10,652	0
Net cash used in investing activities from continuing operations	(302,370)	(67,619)	(8,316)
Net cash provided by (used in) investing activities from discontinued operations	0	161,499	(1,591)
Net cash provided by (used in) investing activities	(302,370)	93,880	(9,907)
Cash flows from financing activities:
Proceeds from stock offering	118,382	0	0
Proceeds from new credit facility, net of fees paid to issuers	378,091	0	0
Repayment of 10 1/4% senior unsecured notes	(237,397)	0	0
Deferred and other financing costs			(22)
Borrowings on line of credit	449,559	1,244,050	1,773,644
Repayments on line of credit	(409,559)	(1,307,872)	(1,791,058)
Principal payments of long-term debt	(5,000)	0	0
Repayments of capital leases	(802)	(3,278)	(2,635)
Net proceeds from exercise of employee stock compensation plans	2,549	8,611	3,198
Surrender of stock to satisfy minimum tax withholding	0	(174)	(189)
Net cash provided by (used in) financing activities	295,823	(58,663)	(17,062)
Net change in cash and cash equivalents	(61,100)	62,101	0
Cash and cash equivalents - beginning of period	62,101	0	0
Cash and cash equivalents - end of period	1,001	62,101	0
DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for interest	22,598	25,589	27,528
Cash paid during the period for income taxes, net of refunds	242	3,137	1,042
DISCLOSURE OF NON-CASH TRANSACTIONS:
Capital lease obligations incurred to acquire property and equipment	$ 145	$ 20	$ 6,631

NATURE OF BUSINESS	12 Months Ended
NATURE OF BUSINESS	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business	NATURE OF BUSINESS Corporate Organization and Business BioScrip, Inc. and subsidiaries (the “Company” or “BioScrip”) is a national provider of home infusion services, home care services and pharmacy benefit management ("PBM") services that partners with patients, physicians, hospitals, home health agencies, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and deliver cost-effective access to prescription medications and home health services. The Company's services are designed to improve clinical outcomes for patients with chronic and acute healthcare conditions while controlling overall healthcare costs. The Company's platform provides broad service capabilities and the ability to deliver clinical management services that offer patients a high-touch, community-based and home-based care environment. The Company's core services are provided in coordination with, and under the direction of, the patient's physician. The Company's multidisciplinary team of clinicians, including pharmacists, nurses, respiratory therapists and physical therapists, work with the physician to develop a plan of care suited to the patient's specific needs. Whether in the home, physician's office, ambulatory infusion center or other alternate sites of care, the Company provides products, services and condition-specific clinical management programs tailored to improve the care of individuals with complex health conditions such as gastrointestinal abnormalities, infectious diseases, cancer, multiple sclerosis, organ transplants, bleeding disorders, immune deficiencies and heart failure. The Company has three operating and reportable segments, "Infusion Services", "Home Health Services" and "PBM Services". These operating and reportable segments reflect how the Company's chief operating decision maker reviews the Company's results in terms of allocating resources and assessing performance. On February 1, 2014, the Company entered into a Stock Purchase Agreement with LHC Group, Inc. and certain of its subsidiaries (collectively, the “Buyers”) wherein the Buyers have agreed to acquire substantially all of the entities and assets that make up the Company’s Home Health Services segment for a total cash purchase price of approximately $60.0 million, subject to a net working capital adjustment. The closing on this transaction is expected to occur on March 31, 2014 (see Note 17 - Subsequent Events). Basis of Presentation The Company’s Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). Reclassifications Certain prior period amounts have been reclassified to conform to the current year presentation. Such reclassifications had no material effect on our previously reported Consolidated Financial Statements.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2013

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]

Summary of Significant Accounting Policies

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Consolidation

The Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Fair Value Measurements

The fair value measurement accounting standard, ASC Topic 820, Fair Value Measurement ("ASC 820"), provides a framework for measuring fair value and defines fair value as the price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The standard establishes a valuation hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on independent market data sources. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available.

The valuation hierarchy is composed of three categories. The categorization within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The categories within the valuation hierarchy are described as follows:


•	Level 1 - Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.


•	Level 2 - Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.


•	Level 3 - Inputs to the fair value measurement are unobservable inputs or valuation techniques.

Cash and Cash Equivalents

Highly liquid investments with a maturity of three months or less when purchased are classified as cash equivalents.

Receivables

Receivables include amounts due from government sources, such as Medicare and Medicaid programs, PBMs, Managed Care Organizations and other commercial insurance (“Plan Sponsors”); amounts due from patient co-payments; amounts due from pharmaceutical manufacturers for rebates; and service fees resulting from the distribution of certain drugs through retail pharmacies.

Allowance for Doubtful Accounts

The allowance for doubtful accounts is based on estimates of losses related to receivable balances. The risk of collection varies based upon the product, the payor (commercial health insurance and government) and the patient’s ability to pay the amounts not reimbursed by the payor. We estimate the allowance for doubtful accounts based on several factors including the age of the outstanding receivables, the historical experience of collections, adjusting for current economic conditions and, in some cases, evaluating specific customer accounts for the ability to pay. Collection agencies are employed and legal action is taken when we determine that taking collection actions is reasonable relative to the probability of receiving payment on amounts owed. Management judgment is used to assess the collectability of accounts and the economic ability of our customers to pay. Judgment is also used to assess trends in collections and the effects of systems and business process changes on our expected collection rates. The Company reviews the estimation process quarterly and makes changes to the estimates as necessary. When it is determined that a customer account is uncollectible, that balance is written off against the existing allowance.

The following table sets forth the aging of our net accounts receivable (net of allowance for contractual adjustments and prior to allowance for doubtful accounts), aged based on date of service and categorized based on the three primary overall types of accounts receivable characteristics (in thousands):



	December 31, 2013				December 31, 2012 ⁽¹⁾
	0 - 180 days	Over 180 days	Total		0 - 180 days	Over 180 days	Total
Government	37,344	9,490	46,834		41,124	2,744	43,868
Commercial	126,498	28,186	154,684		75,389	26,137	101,526
Patient	2,833	2,163	4,996		1,784	4,137	5,921
Gross accounts receivable	166,675	39,839	206,514		118,297	33,018	151,315
Allowance for doubtful accounts			(19,213	)			(22,212	)
Net accounts receivable			187,301				129,103


(1)	The December 31, 2012 balances include the remaining Pharmacy Services gross accounts receivables not sold as part of the 2012 Asset Purchase Agreement of $12.8 million over 180 days and the allowance for doubtful accounts includes $8.0 million related to these receivables. At December 31, 2013, none of the accounts receivable retained by the Company remained.

As of December 31, 2012, excluding the $12.8 million of Pharmacy Services accounts receivable that were remaining, the accounts receivable balance related to the continuing business was $138.5 million, of which $20.2 million were over 180 days. The allowance for doubtful accounts related to the continuing business was $14.2 million or 10.2% of total accounts receivable and 70.2% of accounts receivable over 180 days as of December 31, 2012. As of December 31, 2013, the allowance for doubtful accounts of $19.2 million or 9.3% of total accounts receivable and 48.2% of accounts receivable over 180 days. In addition, the December 31, 2013 aging includes $5.2 million of doubtful account allowances that were established as of the acquisition date of acquired entities or businesses and are not included in the allowance for doubtful accounts above as they are considered a fair value adjustment under purchase accounting. The following table shows the pro forma effect on the accounts receivable aging (in thousands):



	December 31, 2013							December 31, 2012
	0 - 180 days		Over 180 days		Total			0 - 180 days		Over 180 days			Total
Gross accounts receivable	$	166,675	$	39,839	$	206,514		$	118,297	$	33,018		$	151,315
Add: acquisition-related allowance	—		5,243		5,243			—		—			—
Less: Pharmacy Services accounts receivable	—		—		—			—		(12,840		)	(12,840		)
Pro forma gross accounts receivable	$	166,675	$	45,082	211,757			$	118,297	$	20,178		138,475
Allowance for doubtful accounts					(19,213		)						(22,212		)
Add: Acquisition-related allowance					(5,243		)						—
Less: Pharmacy Services allowance					—								8,045
Pro forma allowance for doubtful accounts					(24,456		)						(14,167		)
Pro forma net accounts receivable					$	187,301							$	124,308

The pro forma allowance for doubtful accounts as a percent of pro forma accounts receivable was 11.5% and 10.2% at December 31, 2013 and 2012, respectively.

The Company believes that the increase in the aging is due to insufficient resources given the growth of the business and the resources required to integrate acquired businesses. The Company has added resources, including the engagement of a third party collection firm, and have improved cash and collections process monitoring tools. The Company has added additional controls to mitigate the risk of claims not timely filed. The Company assessed the collectability of the increase in aging and added allowance for doubtful accounts as of December 31, 2013 and believes the accounts receivable, net of the allowance for doubtful accounts, are collectible. Incremental bad debt expense remains a risk if the Company’s action plans implemented in the fourth quarter of 2013 do not have the anticipated level of success.

Allowance for Contractual Discounts

The Company is reimbursed by payors for products and services the Company provides. Payments for medications and services covered by payors are generally less than billed charges. The Company monitors revenue and receivables from payors on an account-specific basis and records an estimated contractual allowance for certain revenue and receivable balances at the revenue recognition date to properly account for anticipated differences between amounts billed and amounts reimbursed. Accordingly, the total revenue and receivables reported in our financial statements are recorded at the amounts expected to be received from these payors. For the significant portion of the Company's revenue, the contractual allowance is estimated based on several criteria, including unbilled claims, historical trends based on actual claims paid, current contract and reimbursement terms and changes in customer base and payor/product mix. Contractual allowance estimates are adjusted to actual amounts as cash is received and claims are settled. We do not believe these changes in estimates are material. The billing functions for the remaining portion of the Company's revenue are largely computerized, which enables on-line adjudication (i.e., submitting charges to third-party payors electronically with simultaneous feedback of the amount the primary insurance plan expects to pay) at the time of sale to record net revenue, exposure to estimating contractual allowance adjustments is limited on this portion of the business.

Inventory

Inventory is recorded at the lower of cost or market. Cost is determined using the first-in, first-out method. Inventory consists principally of purchased prescription drugs and related supplies. Included in inventory is a reserve for inventory waste and obsolescence.

Property and Equipment

Property and equipment is stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of assets as follows:



Asset	Useful Life
Computer hardware and software	3	-	5	years
Office equipment	3	-	5	years
Vehicles	4	-	5	years
Medical equipment	2	-	5	years
Furniture and fixtures			5	years

Leasehold improvements and assets leased under capital leases are depreciated using a straight-line basis over the related lease term or estimated useful life of the assets, whichever is less. The cost and related accumulated depreciation of assets sold or retired are removed from the accounts with the gain or loss, if applicable, recorded in the statement of operations. Maintenance and repair costs are expensed as incurred.

Costs relating to the development of software for internal purposes are charged to expense until technological feasibility is established in accordance with FASB ASC Topic 350, Intangibles – Goodwill and Other (“ASC 350”). Thereafter, the remaining software production costs up to the date placed into production are capitalized and included in Property and Equipment. Costs of customization and implementation of computer software purchased for internal use are likewise capitalized. Depreciation of the capitalized amounts commences on the date the asset is ready for its intended use and is calculated using the straight-line method over the estimated useful life of the software.

Goodwill

Goodwill is not subject to amortization and is tested for impairment annually and whenever events or circumstances exist that indicate that the carrying value of goodwill may no longer be recoverable in accordance with ASC 350. Impairment testing is performed for each of our operating and reporting segments. The impairment testing is based on a two-step process. The first step compares the fair value of a reporting segment to its carrying amount including goodwill. If the first step indicates that the fair value of the reporting unit is less than its carrying amount, the second step must be performed to determine the implied fair value of reporting unit goodwill. The measurement of possible impairment is based on the comparison of the implied fair value of reporting unit goodwill to its carrying value.

Intangible Assets

The Company evaluates the useful lives of its intangible assets to determine if they are finite or indefinite-lived. Our indefinite-lived intangible assets, primarily acquired nursing trademarks and certificates of need, are not subject to amortization and are tested for impairment annually and whenever events or circumstances exist that indicate that their carrying amount may no longer be recoverable. Finite-lived intangible assets, primarily acquired customer relationships, trademarks and non-compete agreements, are amortized on a straight-line basis over their estimated useful lives.

Impairment of Long Lived Assets

The Company evaluates whether events and circumstances have occurred that indicate the remaining estimated useful life of long lived assets, including intangible assets, may warrant revision or that the remaining balance of an asset may not be recoverable. The measurement of possible impairment is based on the ability to recover the balance of assets from expected future operating cash flows on an undiscounted basis. Impairment losses, if any, are determined based on the fair value of the asset, calculated as the present value of related cash flows using discount rates that reflect the inherent risk of the underlying business.

Variable Interest Entity

In accordance with FASB ASC Topic 810, Consolidation, the Company analyzes its variable interests to determine if an entity in which it has a variable interest is a variable interest entity. The Company's analysis includes both quantitative and qualitative reviews. The Company bases its quantitative analysis on the forecasted cash flows of the entity and its qualitative analysis on its review of the design of the entity, its organizational structure, including decision making ability, and relevant financial agreements. The Company also uses its qualitative analysis to determine if it must consolidate a variable interest entity as its primary beneficiary.

The Company had an affiliate equity investment in a variable interest entity that developed a platform that facilitates the flow, management and sharing of vital health and medical information with stakeholders across the healthcare ecosystem. The Company's analysis determined that the Company was not the primary beneficiary and, accordingly, recorded its initial net investment in the variable interest entity of $6.9 million and subsequent working capital contributions in the investments in and advances to unconsolidated affiliate line on the accompanying Consolidated Balance Sheets using the equity method of accounting.

On April 19, 2013, the Company, along with all other minority investors, completed the sale of its affiliate equity investment in this variable interest entity. As of December 31, 2013, the Company had received cash payments from the sale of $8.6 million, with an additional $1.0 million held in escrow. The Company also expects to receive additional services or cash from an existing guarantee during the two years following close. The terms of the services to be provided or the cash guarantee to be paid will be determined by the Company and the parties involved in the sale. As of December 31, 2013, a receivable of $2.2 million is included in other non-current assets in the accompanying Consolidated Balance Sheets.

Amounts due to Plan Sponsors

Amounts due to Plan Sponsors primarily represent payments received from Plan Sponsors in excess of the contractually required reimbursement. These amounts are refunded to Plan Sponsors. These payables also include the sharing of manufacturers’ rebates with Plan Sponsors.

Contingent Consideration

Liabilities that may be owed to sellers after the closing of an acquisition transaction are recorded at fair value as of the opening balance sheet established for the acquired target. These contingent consideration provisions are frequently referred to as earnouts and are the subject of negotiation between the seller and the buyer. An earnout provision can compensate the seller with the value they believe the asset will deliver while also providing downside risk protection to the buyer should projections not materialize. As such, the terms of potential earnouts vary with each transaction. Fair value is assigned using multiple payout scenarios which each have a probability assigned based on factors including actual performance, evidence of business plans that have been implemented, and current market conditions that influence the ability to achieve the earnout. The probable payout amount is discounted to the current balance sheet date using a risk free rate. Each quarter, the fair value of the contingent consideration is updated to reflect relevant factors such as post-closing operating results and future forecasts for the acquired business or entity. The fair value of contingent consideration may be included in current liabilities or other non-current liabilities depending on the payment date specified in the purchase agreement.

Revenue Recognition

The Company generates revenue principally through the sale of prescription drugs and nursing services. Prescription drugs are dispensed either through a pharmacy participating in the Company’s pharmacy network or a pharmacy owned by the Company. Fee-for-service agreements include: (i) pharmacy agreements, where we dispense prescription medications through the Company’s pharmacy facilities and (ii) PBM agreements, where prescription medications are dispensed through pharmacies participating in the Company’s retail pharmacy network.

FASB ASC Subtopic 605-25, Revenue Recognition: Multiple-Element Arrangements (“ASC 605-25”), addresses situations in which there are multiple deliverables under one revenue arrangement with a customer and provides guidance in determining whether multiple deliverables should be recognized separately or in combination. The Company provides a variety of therapies to patients. For infusion-related therapies, the Company frequently provides multiple deliverables of drugs and related nursing services. After applying the criteria from ASC 605-25, the Company concluded that separate units of accounting exist in revenue arrangements with multiple deliverables. Drug revenue is recognized at the time the drug is shipped, and nursing revenue is recognized on the date of service. The Company allocates revenue consideration based on the relative fair value as determined by the Company's best estimate of selling price to separate the revenue where there are multiple deliverables under one revenue arrangement.

Revenue generated under PBM agreements is classified as either gross or net based on whether the Company is acting as a principal or an agent in the fulfillment of prescriptions through our retail pharmacy network. When the Company independently has a contractual obligation to pay a network pharmacy provider for benefits provided to its Plan Sponsors’ members, and therefore is the “primary obligor” as defined in FASB ASC 605, Revenue Recognition ("ASC 605") the Company includes payments (which include the drug ingredient cost) from these Plan Sponsors as revenue and payments to the network pharmacy providers as cost of revenue. These transactions require the Company to pay network pharmacy providers, assume credit risk of Plan Sponsors and act as a principal. If the Company merely acts as an agent, and consequently administers Plan Sponsors’ network pharmacy contracts, the Company does not have the primary obligation to pay the network pharmacy and assume credit risk, and as such, records only the administrative fees (and not the drug ingredient cost) as revenue.

Revenue generated under discount card agreements is recognized when the discount card is used to purchase a prescription drug. The revenue is based on contractual rates per transaction. Broker fees associated with the marketing of the discount cards are incurred and recognized at the time the card is used and classified as selling, general and administrative expense in the Consolidated Statements of Operations.

In the Company’s Infusion Services and Home Health Services segments, the Company also recognizes nursing revenue as the estimated net realizable amounts from patients and Plan Sponsors for services rendered and products provided. This revenue is recognized as the treatment plan is administered to the patient and is recorded at amounts estimated to be received under reimbursement or payment arrangements with payors.

Under the Medicare Prospective Payment System program, net revenue is recorded based on a reimbursement rate which varies based on the severity of the patient’s condition, service needs and certain other factors. Revenue is recognized ratably over a 60-day episode period and is subject to adjustment during this period if there are significant changes in the patient’s condition during the treatment period or if the patient is discharged but readmitted to another agency within the same 60-day episodic period. Medicare cash receipts under the prospective payment system are initially recognized as deferred revenue and are subsequently recognized as revenue over the 60-day episode period. The process for recognizing revenue under the Medicare program is based on certain assumptions and judgments, the appropriateness of the clinical assessment of each patient at the time of certification, and the level of adjustments to the fixed reimbursement rate relating to patients who receive a limited number of visits, have significant changes in condition or are subject to certain other factors during the episode.

Cost of Revenue

Cost of revenue includes the costs of prescription medications, pharmacy claims, fees paid to pharmacies, shipping and other direct and indirect costs associated with pharmacy management and administration, claims processing operations, and nursing services, offset by volume and prompt pay discounts received from pharmaceutical manufacturers and distributors and total manufacturer rebates.

Rebates

Manufacturers’ rebates are part of each of the Company’s segments. Rebates are generally volume-based incentives that are earned and recorded upon purchase of the inventory. Rebates are recorded as a reduction of both inventory and cost of goods sold.

PBM rebates are recorded on historical PBM results and trends and are revised on a regular basis depending on the Company’s latest forecasts, as well as information received from rebate sources. Should actual results differ, adjustments will be recorded in future earnings when the adjustment becomes known. In some instances, rebate payments are shared with the Company’s Plan Sponsors. PBM rebates earned by the Company are recorded as a reduction of cost of goods sold. PBM rebates shared with clients are recorded as a reduction of revenue consistent with the sales incentive provisions of ASC 605.

Lease Accounting

The Company accounts for operating leasing transactions by recording rent expense on a straight-line basis over the expected term of the lease starting on the date it gains possession of leased property. The Company includes tenant improvement allowances and rent holidays received from landlords and the effect of any rent escalation clauses, as adjustments to straight-line rent expense over the expected term of the lease.

Capital lease transactions are reflected as a liability at the inception of the lease based on the present value of the minimum lease payments or, if lower, the fair value of the property. Assets recorded under capital leases are depreciated in the same manner as owned property.

Income Taxes

As part of the process of preparing the Company’s Consolidated Financial Statements, management is required to estimate income taxes in each of the jurisdictions in which it operates. The Company accounts for income taxes under ASC Topic 740, Income Taxes (“ASC 740”). ASC 740 requires the use of the asset and liability method of accounting for income taxes. Under this method, deferred taxes are determined by calculating the future tax consequences attributable to differences between the financial accounting and tax bases of existing assets and liabilities. A valuation allowance is recorded against deferred tax assets when, in the opinion of management, it is more likely than not that the Company will not be able to realize the benefit from its deferred tax assets.

The Company files income tax returns, including returns for its subsidiaries, as prescribed by Federal tax laws and the tax laws of the state and local jurisdictions in which it operates. The Company’s uncertain tax positions are related to tax years that remain subject to examination and are recognized in the Consolidated Financial Statements when the recognition threshold and measurement attributes of ASC 740 are met. Interest and penalties related to unrecognized tax benefits are recorded as income tax expense.

Financial Instruments

The Company’s financial instruments consist mainly of cash and cash equivalents, receivables, accounts payable, accrued interest and its line of credit. The carrying amounts of cash and cash equivalents, receivables, accounts payable, accrued interest and its line of credit approximate fair value due to their fully liquid or short-term nature.

Accounting for Stock-Based Compensation

The Company accounts for stock-based employee compensation expense under the provisions of ASC Topic 718, Compensation – Stock Compensation (“ASC 718”). At December 31, 2013, the Company has two stock-based employee compensation plans pursuant to which incentive stock options (“ISOs”), non-qualified stock options (“NQSOs”), stock appreciation rights ("SARs"), restricted stock, performance shares and performance units may be granted to employees and non-employee directors. Option and stock awards are typically settled by issuing authorized but unissued shares of the Company.

The Company estimates the fair value of each stock option award on the measurement date using a binomial option-pricing model. The fair value of the award is amortized to expense on a straight-line basis over the requisite service period. The Company expenses restricted stock awards based on vesting requirements, including time elapsed, market conditions and/or performance conditions. Because of these requirements, the weighted average period for which the expense is recognized varies. The Company expenses stock appreciation right awards ("SARs") based on vesting requirements. In addition, because they are settled with cash, the fair value of the SAR awards are revalued on a quarterly basis.

Income (Loss) Per Share

The following table sets forth the computation of basic and diluted income (loss) per common share (in thousands, except for per share amounts):



	Year Ended December 31,
	2013			2012			2011
Numerator:
Loss from continuing operations, net of income taxes	$	(53,606	)	$	(8,340	)	$	(424	)
Income from discontinued operations, net of income taxes	(16,048		)	73,047			8,296
Net income (loss)	$	(69,654	)	$	64,707		$	7,872
Denominator - Basic and Diluted:
Weighted average number of common shares outstanding	64,560			56,239			54,505
Earnings Per Common Share:
Loss from continuing operations, basic and diluted	$	(0.83	)	$	(0.15	)	$	(0.01	)
Income (loss) from discontinued operations, basic and diluted	(0.25		)	1.30			0.15
Income (loss) per common share, basic and diluted	$	(1.08	)	$	1.15		$	0.14

The computation of diluted shares for the years ended December 31, 2013, 2012 and 2011 excludes the effect of 3.1 million, 3.4 million and 3.4 million warrants with an exercise price of $10.00 issued in connection with the acquisition of CHS as their inclusion would be anti-dilutive to earnings per common share from continuing operations. In addition, the computation of diluted shares for the years ended December 31, 2013, 2012 and 2011 excludes the effect of 6.1 million, 5.0 million and 4.6 million, respectively, of other common stock equivalents as their inclusion would be anti-dilutive to earnings per common share from continuing operations. ASC Topic 260, Earnings Per Share, requires that income from continuing operations be used as the basis for determining whether the inclusion of common stock equivalents would be anti-dilutive.

Recent Accounting Pronouncements

In July 2012, the FASB issued ASU 2012-02, Testing Indefinite-Lived Intangible Assets for Impairment (“ASU 2012-02”). ASU 2012-02 allows an entity to first assess qualitative factors to determine whether it is necessary to perform a quantitative impairment test. Under this amendment, an entity is not required to calculate the fair value of the indefinite-lived intangible asset unless the entity determines, based on a qualitative assessment, that it is more likely than not that its fair value is less than its carrying amount. The amendments include a number of events and circumstances for an entity to consider in conducting the qualitative assessment. The adoption of this statement did not have a material effect on the Company's Consolidated Financial Statements.

In July 2013, the FASB issued ASU 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”). ASU 2013-11 provides that a liability related to an unrecognized tax benefit would be offset against a deferred tax asset for a net operating loss carryforward, a similar tax loss or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed. In that case, the liability associated with the unrecognized tax benefit is presented in the financial statements as a reduction to the related deferred tax asset for a net operating loss carryforward, a similar tax loss or a tax credit carryforward. In situations in which a net operating loss carryforward, a similar tax loss or a tax credit carryforward is not available at the reporting date under the tax law of the jurisdiction or the tax law of the jurisdiction does not require, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit will be presented in the financial statements as a liability and will not be combined with deferred tax assets. ASU 2013-11 will be effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted. The Company believes that adopting ASU 2013-11 will not have a material impact on its Consolidated Financial Statements.

STOCKHOLDERS' EQUITY (Notes)	12 Months Ended
STOCKHOLDERS' EQUITY (Notes)	Dec. 31, 2013
Stockholders' Equity Attributable to Parent [Abstract]
Stockholders' Equity	STOCKHOLDERS' EQUITY Stock Offering The Company filed a shelf registration statement on Form S-3 on March 18, 2013 and related amendment on April 2, 2013, which was declared effective on April 4, 2013. On April 24, 2013, the Company completed an underwritten primary public offering of 10,406,250 shares of its common stock at an offering price to the public of $12.00 per share. In addition, 3,968,750 shares of common stock were offered and sold by certain existing stockholders in an underwritten secondary offering completed on the same date and at the same offering price to the public. Net proceeds to the Company were $118.4 million after underwriting discounts, commissions and other offering expenses. The Company did not receive any proceeds from the sale of shares of common stock by the selling stockholders. The Company used $21.0 million and approximately $61.1 million of the net proceeds to (i) repay outstanding borrowings under the Company's prior credit facility with Healthcare Finance Group (the "Prior Credit Facility") and (ii) fund a portion of the CarePoint acquisition as described in Note 4 - Acquisitions below, respectively. The Company used the remaining net proceeds from the offering for general corporate purposes, which included, among other things, capital expenditures, repurchases of outstanding debt or equity securities, debt servicing requirements or redemption of our short-term or long-term borrowings, or for other working capital requirements. Treasury Stock During the year ended December 31, 2013, no shares of treasury stock were acquired or issued. During the years ended December 31, 2012 and 2011, 25,999 and 25,273 shares, respectively, were surrendered to satisfy tax withholding obligations on the vesting of restricted stock awards. The Company holds a total of 2,582,520 shares of treasury stock at December 31, 2013 acquired under current and prior repurchase programs as well as forfeitures to satisfy tax obligations in the vesting of restricted stock awards. Common Stock Purchase Warrants In connection with the acquisition of Critical Homecare Solutions Holdings, Inc. ("CHS") in March 2010, the Company issued 3.4 million warrants exercisable for BioScrip common stock. The warrants have a five year term with an exercise price of $10.00 per share. They are exercisable at any time prior to the expiration date. The warrants also contain provisions whereby the number of shares to be issued upon exercise of the warrants will be increased if the Company were to execute certain dilutive transactions such as stock splits, stock dividends or the issuance of shares below 90% of market value at the time of issuance. The Company has determined that the warrants meet the conditions for equity classification in accordance with GAAP. Therefore, these warrants were classified as equity and included in additional paid-in capital. During the year ended December 31, 2013, the Company issued 78,567 shares of common stock pursuant to the cashless exercise of 256,175 of the warrants. As of December 31, 2013, 3.1 million of the warrants remain outstanding. The fair value of the warrants of $12.3 million was calculated as of the acquisition date using the Black-Scholes model. The Black-Scholes model used the following assumptions: volatility of 62%, risk free interest rate of 2.63%, dividend yield of 0% and expected term of five years. In addition, there was a discount applied for lack of marketability of 13.5%. This discount is considered appropriate because the warrants were not registered under the Securities Act of 1933, as amended (the "Securities Act") and the shares issued upon exercise of the warrants will be unregistered shares subject to transfer restrictions.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

ACQUISITIONS

12 Months Ended

Dec. 31, 2013

ACQUISITIONS [Abstract]

Acquisitions

ACQUISITIONS

CarePoint Partners Holdings LLC

On August 23, 2013, the Company closed on the acquisition of substantially all of the assets and assumption of certain liabilities that constituted the home infusion business (the “CarePoint Business”) of CarePoint Partners Holdings LLC, a Delaware limited liability company, and its subsidiaries (collectively "CarePoint"). CarePoint was a provider of home and alternate-site infusion therapy for patients with complex, acute and chronic illnesses. CarePoint serviced approximately 20,500 patients annually through 28 sites of service in nine states in the East Coast and Gulf Coast regions.

The total consideration to the sellers at closing was $211.1 million paid in cash plus a contingent payment of up to $10.0 million. The Sellers of the CarePoint Business will be eligible to receive the contingent payment if the CarePoint Business achieves a specified level of product gross profit during the one-year period following the closing date. Subsequent to the closing, the Company identified additional net working capital adjustments of approximately $2.2 million primarily related to the value of accounts receivable and prepaid expenses as of the date of acquisition and has requested payment from the sellers. The $2.2 million amount due from CarePoint is included in prepaid expenses and other current assets on the accompanying Consolidated Balance Sheets and is reflected in the estimated fair values below.

At the date of acquisition, the fair value of the $10.0 million contingent payment was estimated at $9.8 million and recorded in accrued expenses and other liabilities in the accompanying Consolidated Balance Sheets. The fair value of the contingent payment was determined using Level 3 inputs based on the present value of various payout scenarios, weighted on the basis of probability. At December 31, 2013, the fair value of the contingent payment was re-evaluated using the actual operating results during 2013 and forecasted operating results for 2014 of the CarePoint Business and no adjustment was made.

The Company funded the cash payment at closing with a combination of cash on hand and $150.0 million in borrowings under the Senior Credit Facilities (see Note 9 - Debt).

The table below summarizes the Company's preliminary assessment of the estimated fair values of the assets acquired and liabilities assumed as of the date of Closing of the acquisition of the CarePoint Business. The Company will finalize these amounts as it obtains the information necessary to complete the measurement process. Any changes resulting from facts and circumstances that existed as of the date of the Closing may result in retrospective adjustments to the provisional amounts recognized. These changes could be significant. The Company will finalize these amounts no later than one year from the acquisition date.



	Estimated Fair Value (in thousands)
Cash	$	14
Accounts receivable	16,644
Inventories	3,263
Other current assets	272
Property and equipment	3,266
Identifiable intangible assets⁽¹⁾	16,700
Current liabilities	(8,128		)
Non-current liabilities	(621		)
Total identifiable net assets	31,410
Goodwill	187,228
Total cash and fair value of contingent consideration	$	218,638


(1)	The following table summarizes the provisional amounts and useful lives assigned to identifiable intangible assets:



	Weighted- Average Useful Lives	Amounts Recognized as of the Closing Date (in thousands)
Customer relationships	2 - 4 years	$	13,600
Trademarks	2 years	2,600
Non-compete agreements	5 years	500
Total identifiable intangible assets acquired		$	16,700

The excess of the purchase price over the fair value of tangible and identifiable intangible assets acquired and liabilities assumed in the acquisition was allocated to goodwill. The value of goodwill represents the value the Company expects to be created by combining the various operations of the CarePoint Business with the Company's operations, including the expansion into new infusion markets, the opportunity to consolidate and upgrade certain existing facilities, access to new patients and potential cost savings and synergies. The CarePoint transaction was structured such that the amount allocated to goodwill will be deductible for income tax purposes.

The accompanying Consolidated Statements of Operations for the year ended December 31, 2013 include revenues and income from continuing operations of the CarePoint Business of $55.8 million and $2.3 million.

HomeChoice Partners, Inc.

On February 1, 2013, the Company acquired 100% of the ownership interest in HomeChoice Partners, Inc., a Delaware corporation ("HomeChoice"). Prior to the Company's acquisition, HomeChoice was a provider of alternate-site infusion pharmacy services that serviced approximately 15,000 patients annually and had 14 infusion pharmacy locations in Pennsylvania, Washington, DC, Maryland, Virginia, North Carolina, South Carolina, Georgia, Missouri, and Alabama.

The cash purchase price of the HomeChoice acquisition was $72.9 million paid at the closing date. In addition, the purchase price may be increased by contingent consideration of up to $20.0 million if HomeChoice reaches certain performance milestones in the two years following the closing.

At the date of acquisition, the fair value of the potential contingent consideration, using Level 3 inputs, was estimated at $8.0 million. The $20.0 million maximum amount of the contingent consideration was based on high growth targets that were an incentive for the sellers to partner with the Company to drive performance in excess of the assumptions under the transaction valuation model. The opportunities to outperform the transaction valuation model were quantified and used in the Company's initial fair value assessment at the acquisition date. Because the performance thresholds required to earn the contingent consideration were high, the Company assigned lower than a 50% probability of payout to the various payout scenarios considered when we estimated the initial fair value of $8.0 million. At December 31, 2013, the fair value of the contingent payment was re-evaluated using the actual operating results during 2013 and forecasted operating results for 2014 to adjust the present value and probability of the various payout scenarios. Specifically, the 2013 operating results indicated that the sellers would not earn the $10.0 million maximum payout for the first year. Additionally, the remaining $10.0 million maximum payout related to the second year was less likely to be earned given the growth required above current projections necessary to achieve the payout target. While the acquisition has generated expected revenues forecasted in the transaction valuation model, it did not exceed the model sufficiently to earn additional contingent consideration. As a result of this reevaluation, the fair value of the contingent payment was reduced to $2.2 million and is included in other non-current liabilities in the accompanying Consolidated Balance Sheets. The $5.8 million of income resulting from the reduction in the fair value of the contingent liability is included in change in fair value of contingent consideration in the accompanying Consolidated Statements of Operations for the year ended December 31, 2013.

The Company funded the acquisition with a combination of cash and the Prior Credit Facility.

The table below summarizes the Company's assessment of the fair values of the assets acquired and liabilities assumed as of the acquisition date of HomeChoice.



	Fair Value (in thousands)
Accounts receivable	$	9,693
Inventories	1,984
Other current assets	154
Property and equipment	2,432
Identifiable intangible assets⁽¹⁾	4,000
Other non-current assets	30
Current liabilities	(4,073		)
Total identifiable net assets	14,220
Goodwill	66,701
Total cash and fair value of contingent consideration	$	80,921


(1)	The following table summarizes the provisional amounts and useful lives assigned to identifiable intangible assets:



	Weighted- Average Useful Lives	Amounts Recognized as of Acquisition Date (in thousands)
Customer relationships	5 mo. - 3 years	$	2,000
Trademarks	23 months	1,000
Non-compete agreements	1 year	1,000
Total identifiable intangible assets acquired		$	4,000

The excess of the purchase price over the fair value of tangible and identifiable intangible assets acquired and liabilities assumed in the acquisition was allocated to goodwill. The value of goodwill represented the value the Company expected to be created by combining the various operations of HomeChoice with the Company's operations, including the expansion into new infusion markets, the opportunity to consolidate and upgrade certain existing facilities, access to new patients and potential cost savings and synergies. The HomeChoice transaction was structured such that the amount allocated to goodwill will be deductible for income tax purposes.

The accompanying Consolidated Statements of Operations for the year ended December 31, 2013 includes revenues and income from continuing operations related to HomeChoice for the period from the date of acquisition through December 31, 2013, of $67.7 million and $2.6 million, respectively.

InfuScience, Inc.

On July 31, 2012, the Company acquired 100% of InfuScience, Inc. (“InfuScience”) for a cash payment of $38.3 million. The purchase price could increase up to an additional $3.0 million based on the results of operations during the 24 month period through July 31, 2014. InfuScience historically acquired, developed and operated businesses providing alternate site infusion pharmacy services through 5 infusion centers located in Eagan, Minnesota; Omaha, Nebraska; Chantilly, Virginia; Charleston, South Carolina; and Savannah, Georgia.

At the date of acquisition, the fair value of the potential contingent payments of $3.0 million was estimated at $2.9 million. The fair value of the contingent liability was determined using Level 3 inputs based on the present value of various payout scenarios, weighted on the basis of probability. As of December 31, 2013, the Company has made contingent payments of $1.7 million based on the achievement of expected operating results. At December 31, 2013, the fair value of the remaining contingent liability was reevaluated using actual operating results during 2013, forecasted operating results for 2014 and payments made through December 31, 2013 to adjust the present value and probability of the various payout scenarios. As a result of this reevaluation, the fair value of the contingent payment was increased to $1.3 million and is included in accrued expenses and other current liabilities in the accompanying Consolidated Balance Sheets. The $0.1 million of expense resulting from the increase in the fair value of the contingent liability is included in change in fair value of contingent consideration in the accompanying Consolidated Statements of Operations for the year ended December 31, 2013.

The table below summarizes the Company's assessment of the fair values of the assets acquired and liabilities assumed as of the acquisition date of InfuScience.



	Fair Value (in thousands)
Cash	$	23
Accounts receivable	4,938
Inventories	586
Other current assets	371
Property and equipment	751
Identifiable intangible assets⁽¹⁾	400
Other non-current assets	349
Current liabilities	(4,428		)
Total identifiable net assets	2,990
Goodwill	38,429
Total cash and fair value of contingent consideration	$	41,419


(1)	The following table summarizes the provisional amounts and useful lives assigned to identifiable intangible assets:



	Weighted- Average Useful Lives (Months)	Amounts Recognized as of Acquisition Date (in thousands)
Customer relationships	5 months	$	400
Total identifiable intangible assets acquired		$	400

The excess of the purchase price over the fair value of tangible and identifiable intangible assets acquired and liabilities assumed in the acquisition was allocated to goodwill. The value of goodwill represented the value the Company expected to be created by combining the various operations of InfuScience with the Company's operations, including the ability to cross-sell their respective services on a national basis with an expanded footprint in Infusion Services segment. Of the goodwill recorded in the InfuScience acquisition, $7.7 million is estimated to be deductible for income tax purposes.

The accompanying Consolidated Statements of Operations for the year ended December 31, 2013 includes revenues of $46.7 million and income from operations of $4.4 million related to the operations of InfuScience. Revenues and loss from continuing operations for the year ended December 31, 2012, include revenues of $16.5 million and a loss from operations of $1.7 million related to InfuScience from the date of acquisition through December 31, 2012.

Acquisition and Integration Costs

Acquisition and integration expenses in the accompanying Consolidated Statements of Operations for the years ended December 31, 2013 and 2012 include the following costs related to the CarePoint Business, HomeChoice Partners, and InfuScience acquisitions (in thousands):



	Year Ended December 31,
	2013		2012
Legal and professional fees	$	5,113	$	2,941
Financial advisory fees	4,713		—
Employee costs including redundant salaries and benefits and severance	3,554		806
Facilities consolidation and discontinuation	1,621		110
Other	1,129		189
Total	$	16,130	$	4,046

There were no acquisition and integration expenses in the year ended December 31, 2011.

Pro Forma Impact of Acquisitions

The following table shows summarized unaudited pro forma combined operating results of the Company as if the InfuScience acquisition had occurred on the same terms as of January 1, 2011 and the HomeChoice and CarePoint Business acquisitions had occurred on the same terms as of January 1, 2012. Pro forma adjustments have been made related to amortization of intangibles, interest expense, and income tax expense. The pro forma financial information does not reflect revenue opportunities and cost savings which the Company expected to realize as a result of the acquisitions or estimates of charges related to the integration activity. Amounts are in thousands, except for earnings per share:



	Year Ended December 31,
	2013			2012			2011
Revenues	$	949,679		$	893,814		$	589,333
Net loss from continuing operations	$	(55,444	)	$	(23,352	)	$	(2,582	)
Basic loss per common share from continuing operations	$	(0.86	)	$	(0.42	)	$	(0.05	)
Diluted loss per common share from continuing operations	$	(0.86	)	$	(0.42	)	$	(0.05	)

The unaudited pro forma combined results of operations were prepared using the acquisition method of accounting and are based on the historical financial operating results of the Company, CarePoint Business, HomeChoice and InfuScience. Except to the extent realized in the years ended December 31, 2013 and 2012, the unaudited pro forma information does not reflect any cost savings, operating synergies and other benefits that the Company may achieve as a result of these acquisitions, or the expenses to be incurred to achieve these savings, operating synergies and other benefits. In addition, except to the extent recognized in the years ended December 31, 2013 and 2012, the unaudited pro forma information does not reflect the costs to integrate the operations of the Company with CarePoint Business, HomeChoice and InfuScience.

The unaudited pro forma information is not necessarily indicative of what the Company's consolidated results of operations actually would have been had the CarePoint Business and HomeChoice acquisitions been completed on January 1, 2012 and the InfuScience acquisition been completed on January 1, 2011. In addition, the unaudited pro forma information does not purport to project the future results of operations of the Company. The unaudited pro forma information primarily reflects the following net adjustments to the historical results of the acquired entities prior to acquisition (in thousands):



	Year Ended December 31,
	2013		2012		2011
Interest expense	$	3,734	$	8,613	$	1,169
Amortization expense	$	576	$	4,094	$	400
Income tax expense (benefit)	$	2,785	$	4,357	$	(1,159	)

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6996-128479

+ Details

DISCONTINUED OPERATIONS DISCONTINUED OPERATIONS (Notes)

12 Months Ended

Dec. 31, 2013

DISCONTINUED OPERATIONS [Abstract]

Discontinued Operations

NOTE 5-- DISCONTINUED OPERATIONS

On February 1, 2012, the Company and certain of its subsidiaries (collectively, the "Sellers") entered into a purchase agreement (the “2012 Asset Purchase Agreement”) with Walgreen Co. and certain of its subsidiaries (collectively, the "Pharmacy Services Buyers") with respect to the sale of certain assets, rights and properties (the “Pharmacy Services Asset Sale”) relating to the Sellers' traditional and specialty pharmacy mail operations and community retail pharmacy stores.

Pursuant to the terms of the 2012 Asset Purchase Agreement, the Company received a total purchase price of approximately $173.8 million during 2012, including approximately $158.8 million at closing on May 4, 2012 (which included monies received for the inventories on hand attributable to the operations subject to the Pharmacy Services Asset Sale) and a subsequent additional purchase price payment of $15.0 million based on events related to the Pharmacy Services Buyer's retention of certain business after closing. Similarly, the Company may have been required to refund up to approximately $6.4 million of the cash received to the Buyers under certain circumstances during the 14 month period following the closing. During the three months ended September 30, 2013, the contingency was resolved with no refund due to the Buyers and the Company included the amount of this liability in the gain on sale. The $173.8 million purchase price excluded all accounts receivable and working capital liabilities relating to the operations subject to the sale, which were retained by the Company. The net accounts receivable retained by the Company were approximately $0.0 and $4.8 million at December 31, 2013 and 2012, respectively.

The Pharmacy Services Asset Sale included the sale of 27 community pharmacy locations and certain assets of three community pharmacy locations and three traditional and specialty mail service operations, which constituted all of the Company's operations in the community pharmacy and mail order lines of business. Two mail order locations which were not transferred as part of the Pharmacy Services Asset Sale have been redeployed to provide infusion pharmacy services.

On May 4, 2012, the carrying value of the assets included in the Pharmacy Services Asset Sale was as follows (in thousands):



	Carrying Value
Inventory	$	30,560
Prepaid expenses and other current assets	299
Total current assets	30,859
Property and equipment, net	1,592
Goodwill	11,754
Intangible assets, net	2,503
Total assets	$	46,708

In addition, the Company and its subsidiaries and certain subsidiaries of the Pharmacy Services Buyers entered into an agreement concurrently with the 2012 Asset Purchase Agreement which provided that the Company cease to be the sole fulfillment pharmacy for customers who utilized the drugstore.com website. The agreement provided for a cash payment of $3.0 million to the Company and the payment of $2.9 million to the Pharmacy Services Buyers related to contingent consideration from the Company's 2010 acquisition of the prescription pharmacy business of DS Pharmacy, Inc. both of which occurred during the year ended December 31, 2012.

As a result of the divestiture process, the Company's management commenced an assessment of the Company's continuing operations in order to align its corporate structure with its remaining operations. As part of these efforts, the Company has incurred and expects to continue to incur additional charges that may impact the Company's future consolidated financial statements (see Note 7 - Restructuring Expenses). These additional charges include employee severance, other restructuring type charges, temporary redundant expenses, potential cash bonus payments, bad debt expense relating to retained receivables, the write down of certain long-lived assets and potential accelerated payments or terminated costs for certain of its contractual obligations. Interest expense was allocated to discontinued operations based upon the portion of the borrowing base associated with discontinued operations. Income tax expense has also been allocated to discontinued operations. These adjustments have been made for all periods presented. Depreciation expense was no longer incurred on fixed assets included in the disposal group as of February 1, 2012, the date the Company entered into the 2012 Asset Purchase Agreement.

As a result of the Pharmacy Services Asset Sale, the Company recognized a total pretax gain of $108.2 million including a pretax gain of $101.6 million net of transaction costs of $5.6 million during the year ended December 31, 2012. The Company also recognized approximately $13.4 million of impairment costs, employee severance and other benefit-related costs, and facility-related costs as a result of the transaction in the year ended December 31, 2012 (see Note 8 - Property and Equipment). The impairment costs, employee severance and other benefit-related costs, facility-related costs, and other one-time charges are included in income (loss) from discontinued operations, net of income taxes in the Consolidated Statements of Operations. The Company allocated tax expense of $6.1 million to discontinued operations' pre-tax income of $79.2 million during the year ended December 31, 2012. The allocated tax expense is less than the statutory rate because the Company used $24.1 million of deferred tax assets that previously had a full valuation allowance. The use of the deferred tax assets significantly reduced the amount of gain that was subject to federal and state income tax.

The Company recognized approximately $7.6 million of other costs during the year ended December 31, 2013, primarily legal and other fees associated with the settlements discussed below and collection fees for the retained accounts receivable.

Effective January 8, 2014, the Company entered into a Stipulation and Order of Settlement and Dismissal (the “Federal Settlement Agreement”) with the U.S. Department of Justice (the “DOJ”) and a qui tam relator (the “Relator”). The Federal Settlement Agreement memorialized the federal and private component of an agreement in principle to settle all civil claims under the False Claims Act and related statutes and all common law claims that could have been brought by the DOJ and Relator that arose out of the distribution of the Novartis Pharmaceutical Corporation’s product Exjade® (the “Medication”) by the Company's traditional and specialty pharmacy mail operations and community retail pharmacy stores prior to its divestiture in May 2012. Further, effective February 11, 2014, the Company entered into State Settlement Agreements with the offices of the Attorneys General of thirty-five states (the "Settling States"). The State Settlement Agreements memorialized the state component of the Company's agreement in principle to settle the claims that could have been brought by the Settling States that arose out of the distribution of the Medication. During the year ended December 31, 2013, the Company accrued $15.0 million related to the Settlement Agreements and included the amount and related legal fees and expenses in income (loss) from discontinued operations, net of income taxes in the Consolidated Statements of Operations (see Note 10 - Commitments and Contingencies).

As of December 31, 2013, there were accruals of $16.3 million related to legal settlement, employee severance and other costs, of which $4.3 million is included in accrued expenses and other current liabilities and $12.0 million is included in other non-current liabilities on the Consolidated Balance Sheets. The accrual activity consisted of the following (in thousands):



	Legal Settlement		Impairment Costs			Employee Severance and Other Benefits			Facility-Related Costs			Other Costs			Total
Balance at December 31, 2011	$	—	$	—		$	—		$	—		$	—		$	—
Expenses	—		5,839			5,279			1,071			1,198			13,387
Cash payments	—		—			(5,234		)	(82		)	(3,133		)	(8,449		)
Non-cash charges	—		(5,839		)	—			(989		)	2,024			(4,804		)
Balance at December 31, 2012	—		—			45			—			89			134
Expenses	15,000		—			186			—			7,410			22,596
Cash payments	—		—			(103		)	—			(6,261		)	(6,364		)
Non-cash charges	—		—			(36		)	—			(43		)	(79		)
Balance at December 31, 2013	$	15,000	$	—		$	92		$	—		$	1,195		$	16,287

The operating results of the divested traditional and specialty pharmacy mail operations and community pharmacies for the years ended December 31, 2013, 2012 and 2011 are summarized below (in thousands):



	Years ended December 31,
	2013			2012		2011
Revenue	$	(75	)	$	466,747	$	1,263,520
Gross profit	(519		)	29,844		96,888
Operating expenses	7,118			38,612		77,727
Legal settlement expense	15,000			—		—
Bad debt expense	—			12,931		7,213
Interest (income) expense	(41		)	761		2,764
Gain on sale	6,548			101,624		—
Income tax expense	—			6,117		888
Income (loss) from discontinued operations, net of income taxes	$	(16,048	)	$	73,047	$	8,296

- Definition

The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1436-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

+ Details

GOODWILL AND INTANGIBLE ASSETS

12 Months Ended

Dec. 31, 2013

GOODWILL AND INTANGIBLE ASSETS [Abstract]

Goodwill and Intangible Assets

GOODWILL AND INTANGIBLE ASSETS

Goodwill, and the changes in the carrying amount of goodwill by operating and reportable segment for the years ended December 31, 2013 and 2012, are as follows (in thousands):



	Infusion Services		Home Health Services		PBM Services		Total
Balance at December 31, 2011	$	265,859	$	33,784	$	12,744	$	312,387
Acquisitions	38,423		—		—		38,423
Balance at December 31, 2012	$	304,282	$	33,784	$	12,744	$	350,810
Acquisitions	254,304		—		—		254,304
Other adjustments	7		—		—		7
Balance at December 31, 2013	$	558,593	$	33,784	$	12,744	$	605,121

The Company evaluated goodwill for possible impairment in accordance with ASC 350, Intangibles--Goodwill and Other (see Note 2 - Significant Accounting Policies) as of December 31, 2013, and determined that no impairment of goodwill was indicated.

Intangible assets consisted of the following as of December 31, 2013 and 2012 (in thousands):



	December 31, 2013							December 31, 2012
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Indefinite Lived Assets
Home Health certificates of need	$	9,600	$	—		$	9,600	$	9,600	$	—		$	9,600
Home Health nursing trademarks	5,800		—			5,800		5,800		—			5,800
	15,400		—			15,400		15,400		—			15,400
Finite Lived Assets
Infusion customer relationships	25,650		(12,062		)	13,588		9,300		(7,447		)	1,853
Infusion trademarks	6,200		(3,514		)	2,686		2,600		(2,407		)	193
Non-compete agreements	1,500		(950		)	550		—		—			—
	33,350		(16,526		)	16,824		11,900		(9,854		)	2,046
	$	48,750	$	(16,526	)	$	32,224	$	27,300	$	(9,854	)	$	17,446

Indefinite lived intangible assets are not subject to amortization. Finite lived intangible assets are amortized on a straight-line basis over their estimated useful lives as follows:



		Estimated Useful Life
Infusion customer relationships		5 months - 4 years
Infusion trademarks		23 months - 3 years
Non-compete agreements		1 to 5 years

Total amortization expense of intangible assets was $6.7 million, $4.0 million, and $3.4 million for the years ended December 31, 2013, 2012, and 2011, respectively. Amortization expense is expected to be the following (in thousands):



Year ending December 31,	Estimated Amortization
2014	$	5,571
2015	4,966
2016	2,622
2017	2,385
2018	1,221
Thereafter	$	59
Total estimated amortization expense	$	16,824

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

RESTRUCTURING EXPENSE

12 Months Ended

Dec. 31, 2013

RESTRUCTURING AND OTHER EXPENSES [Abstract]

Restructuring and Other Expenses

RESTRUCTURING AND OTHER EXPENSES

Restructuring and other expenses include expenses resulting from the execution of our strategic assessment and related restructuring plans, consisting primarily of employee severance and other benefit-related costs, third-party consulting costs, facility-related costs, and certain other costs. It also includes other transitional costs such as training, redundant salaries prior to defined separation dates, and retention bonuses for certain critical personnel.

In 2010, the Company commenced a strategic assessment of its business and operations ("Restructuring Phase I"). This assessment focused on expanding revenue opportunities and lowering corporate overhead, including workforce and benefit reductions and facility rationalization. In addition to addressing corporate overhead, the strategic assessment examined the Company's market strengths and opportunities and compared the Company's position to that of its competitors. As a result of the assessment, the Company focused its growth on investments in the Infusion and Home Health Services segments and elected to pursue offers for its traditional and specialty pharmacy mail operations and community retail pharmacy stores. Accordingly, the Company consummated the Pharmacy Services Asset Sale relating to its traditional and specialty pharmacy mail operations and community retail pharmacy stores.

In 2012, as a result of the divestiture process, the Company's management team commenced an assessment of the Company's continuing operations in order to align its corporate structure with its remaining operations ("Restructuring Phase II").

The Company anticipates that additional restructuring will occur and thus we may incur significant additional charges such as the write down of certain long-lived assets, employee severance, other restructuring type charges, temporary redundant expenses, potential cash bonus payments and potential accelerated payments or termination costs for certain of its contractual obligations, which impact the Company's future Consolidated Financial Statements.

Restructuring Phase I

As a result of the execution of the strategic assessment and related restructuring plan, the Company incurred restructuring expenses of approximately $(0.1) million, $0.2 million and $6.4 million during the years ended December 31, 2013, 2012 and 2011, respectively. The Company did not incur any significant restructuring expenses related to Restructuring Phase I during 2013, though some amounts previously accrued were adjusted. Restructuring expenses during the year ended December 31, 2012 consisted of approximately $0.3 million of third-party consulting costs offset by $0.1 million of facility-related expense adjustments. Restructuring expenses during the year ended December 31, 2011 consisted of approximately $2.9 million of third-party consulting costs and $1.9 million of severance and other benefit-related costs related to workforce reductions, and $1.6 million of facility-related costs.

Since inception of the strategic assessment and related restructuring plan, the Company has incurred approximately $10.1 million in total expenses, including $4.3 million of third-party consulting costs, $4.1 million of employee severance and other benefit-related costs related to workforce reductions, and $1.7 million of facility-related costs. A large part of the third-party consulting costs and other costs were associated with the analysis of our assets and their long-term strategic value relative to other assets in which we could invest. The assessment process culminated in the Pharmacy Services Asset Sale (see Note 5--Discontinued Operations).

The restructuring costs are included in restructuring and other expenses on the Consolidated Statements of Operations. As of December 31, 2013, there are restructuring accruals of $0.5 million related to Phase I included in accrued expenses and other current liabilities and other non-current liabilities on the Consolidated Balance Sheets. The restructuring accrual activity consisted of the following (in thousands):



	Employee Severance and Other Benefits			Consulting Costs			Facility-Related Costs			Other Costs		Total
Balance as of December 31, 2011	$	2,109		$	50		$	1,289		$	—	$	3,448
Expenses	6			270			(61		)	—		215
Cash payments	(1,952		)	(300		)	(387		)	—		(2,639		)
Balance as of December 31, 2012	$	163		$	20		$	841		$	—	$	1,024
Expenses	(163		)	(20		)	118			—		(65		)
Cash payments	—			—			(438		)	—		(438		)
Balance as of December 31, 2013	$	—		$	—		$	521		$	—	$	521

Restructuring Phase II

As a result of Restructuring Phase II, the Company incurred restructuring expenses of approximately $3.4 million and $1.9 million during the years ended December 31, 2013 and 2012. The Company did not incur restructuring expense related to Phase II during 2011. Restructuring expenses during the year ended December 31, 2013 consisted of approximately $1.5 million of employee severance and other benefit related costs associated with workforce reductions, $1.6 million of third-party consulting costs and $0.4 million in other costs. Restructuring expenses during the year ended December 31, 2012 consisted of approximately $1.1 million of employee severance and other benefit related costs associated with workforce reductions, $0.3 million of third-party consulting costs, and $0.5 million in other costs.

The restructuring costs are included in restructuring and other expenses on the Consolidated Statements of Operations. As of December 31, 2013, there are restructuring accruals of $2.5 million related to Phase II included on the Consolidated Balance Sheets. The restructuring accrual activity consisted of the following (in thousands):



	Employee Severance and Other Benefits			Consulting Costs			Facility-Related Costs		Other Costs			Total
Balance as of December 31, 2011	$	—		$	—		$	—	$	—		$	—
Expenses	1,125			262			—		541			1,928
Cash payments	(566		)	(117		)	—		(541		)	(1,224		)
Balance as of December 31, 2012	$	559		$	145		$	—	$	—		$	704
Expenses	1,496			1,561			—		378			3,435
Cash payments	(1,159		)	(155		)	—		(344		)	(1,658		)
Balance as of December 31, 2013	$	896		$	1,551		$	—	$	34		$	2,481

Other transitional costs included in restructuring and other expenses on the Consolidated Statements of Operations totaled $4.4 million, $3.0 million, and $1.5 million in the years ended December 31, 2013, 2012 and 2011, respectively. During the year ended December 31, 2012 they also include $0.8 million for certain state sales taxes associated with prior year sales.

PROPERTY AND EQUIPMENT

12 Months Ended

Dec. 31, 2013

Property, Plant and Equipment [Abstract]

Property and Equipment

PROPERTY AND EQUIPMENT

Property and equipment consists of the following (in thousands):



	December 31,
	2013			2012
Computer and office equipment, including equipment acquired under capital leases	$	20,440		$	14,443
Software capitalized for internal use	13,842			9,939
Vehicles, including equipment acquired under capital leases	2,056			1,540
Medical equipment	22,391			16,466
Work in progress	8,820			4,315
Furniture and fixtures	4,461			3,219
Leasehold improvements	12,232			7,164
Property and equipment, gross	84,242			57,086
Less: Accumulated depreciation	(42,630		)	(33,365		)
Property and equipment, net	$	41,612		$	23,721

Work in progress at December 31, 2013 and 2012 includes $0.7 million and $1.3 million, respectively, of internally developed software costs to be capitalized.

Depreciation expense, including expense related to assets under capital lease, for the years ended December 31, 2013, 2012 and 2011 was $13.6 million, $8.5 million, and $6.6 million, respectively. Depreciation expense for the years ended December 31, 2013, 2012 and 2011 includes $1.7 million, $1.3 million, and $0.8 million, respectively, related to costs related to software capitalized for internal use.

Impairment

The Company assesses the impairment of its assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. As a result of the Pharmacy Services Asset Sale (see Note 5 - Discontinued Operations), the Company evaluated certain facilities that were retained by the Company following the divestiture. As a result of the evaluation, the Company determined that a triggering event occurred, giving rise to the need to assess the recoverability of certain of our assets previously used in the specialty pharmacy mail operations and community retail pharmacy operations, which consisted primarily of software capitalized for internal use, leasehold improvements and work in progress. Based on our analysis, we recorded a $5.8 million impairment charge in income (loss) from discontinued operations, net of income taxes during the year ended December 31, 2012. No impairment charges were incurred during the years ended years ended December 31, 2013 and December 31, 2011.

DEBT

12 Months Ended

Dec. 31, 2013

DEBT [Abstract]

Debt

DEBT

As of December 31, 2013 and 2012 the Company’s debt consisted of the following (in thousands):



	December 31,
	2013		2012
Revolving Credit Facility	$	40,003	$	—
Term Loan Facilities	395,000		—
Prior Credit Facility	—		—
2015 Notes	—		225,000
Capital leases	577		1,379
Total Debt	435,580		226,379
Less: Current portion	60,257		953
Long-term debt, net of current portion	$	375,323	$	225,426

Senior Credit Facilities

On July 31, 2013, the Company entered into (i) a senior secured first-lien revolving credit facility in an aggregate principal amount of $75.0 million (the “Revolving Credit Facility”), (ii) a senior secured first-lien term loan B in an aggregate principal amount of $250.0 million (the “Term Loan B Facility”) and (iii) a senior secured first-lien delayed draw term loan B in an aggregate principal amount of $150.0 million (the “Delayed Draw Term Loan Facility” and, together with the Revolving Credit Facility and the Term Loan B Facility, the “Senior Credit Facilities”) with SunTrust Bank, Jefferies Finance LLC and Morgan Stanley Senior Funding, Inc.

Advances under the Senior Credit Facilities bear interest at a floating rate or rates equal to the Eurodollar rate plus 5.25% or the base rate plus 4.25% specified in the Senior Credit Facilities agreement. The Eurodollar rate used in the interest rate calculation for Term Loan B Facility and the Delayed Draw Term Loan Facility (collectively, the "Term Loan Facilities") is subject to a floor of 1.25%. There is no floor applied to interest rate calculation for the Revolving Credit Facility. In addition, there is a 0.50% commitment fee on the unused portion of the Revolving Credit Facility. As of December 31, 2013, the interest rate for the Term Loan Facilities is approximately 6.50% and the interest rate for the Revolving Credit Facility is approximately 5.46%. The interest rates may vary in the future depending on the Company's consolidated net leverage ratio.

The Revolving Credit Facility matures on July 31, 2018, at which time all principal amounts outstanding are due and payable. The Term Loan Facilities each mature on July 31, 2020, and require equal consecutive quarterly repayments of 1.25% of the original principal amount funded commencing on December 31, 2013. Once repaid, amounts under Term Loan Facilities may not be re-borrowed. The Senior Credit Facilities are secured by substantially all of the Company's and its subsidiaries' assets.

The Senior Credit Facilities contain customary events of default that include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material indebtedness and events constituting a change of control. The occurrence of certain events of default may increase the applicable rate of interest by 2% and could result in the acceleration of the Company's obligations under the Senior Credit Facilities to pay the full amount of the obligations. If the Company draws down in excess of 25% of the available borrowing capacity under the Revolving Credit Facility, the net leverage covenants under the Revolving Credit Facility will become applicable such that the Company’s consolidated net leverage ratio will not be permitted to exceed certain thresholds until maturity of the Revolving Credit Facility. The required maximum consolidated net leverage ratio thresholds for the Revolving Credit Facility are defined for each measurement quarter. The Term Loan Facilities are not subject to any financial covenants. The Company was in compliance with the net leverage covenants under the Revolving Credit Facility at December 31, 2013.

The proceeds of the Term Loan B Facility were used to refinance certain existing indebtedness of the Company, including the payment of the purchase price for the 10 1/4% senior unsecured notes (the "2015 Notes") tendered and accepted for purchase in the Offer (defined below) and the payment of the redemption price for the 2015 Notes that remained outstanding after completion of the Offer. The Delayed Draw Term Loan Facility and the Revolving Credit Facility were used to fund a portion of the CarePoint Business acquisition and may be used for other general corporate purposes of the Company, including acquisitions, investments, capital expenditures and working capital needs.

On December 23, 2013, the Company entered into the First Amendment to the Senior Credit Facilities pursuant to which the Company obtained the required consent of the lenders to enter into the Settlement Agreements (see Note 10 - Commitments and Contingencies) and to begin making payments, in accordance with the payment terms, on the settlement amount of $15.0 million. In exchange for this consent, the Company paid the lenders a fee of $0.5 million and included this amount in loss from discontinued operations in the Consolidated Statements of Operations.

Subsequent to December 31, 2013, the Company entered into the Second Amendment to the Senior Credit Facilities (see Note 17 - Subsequent Events).

Prior Revolving Credit Facility

On July 3, 2012, the Company entered into a Third Amendment to the Second Amended and Restated Credit Agreement, by and among the Company, as borrower, all of its subsidiaries as guarantors thereto, the lenders, Healthcare Finance Group, LLC, an administrative agent, and the other parties thereto to provide an available line of credit of up to $125.0 million. The Prior Credit Facility bore interest at LIBOR rate plus 3.5%. On July 31, 2013, the Company entered into its new Senior Credit Facilities and terminated this agreement. At the date of termination, no amounts were outstanding under this agreement.

10¼% Senior Unsecured Notes due 2015

On June 3, 2013, the Company commenced an Offer to Purchase and Consent Solicitation (the "Offer") to the holders of the Company's outstanding $225.0 million aggregate principal 2015 Notes to purchase any and all of the 2015 Notes at $1,056.25 cash for each $1,000.00 of principal plus accrued but unpaid interest to the date of purchase.

On July 31, 2013, the Company received and accepted for purchase approximately 56.1% of the aggregate principal amount of its outstanding 2015 Notes that were validly tendered by the Offer's expiration date of July 30, 2013. The $133.3 million aggregate repurchase price plus accrued but unpaid interest of $4.3 million, of the 2015 Notes tendered in connection with the Offer was paid from proceeds received under the Term Loan B Facility.

In connection with the Offer, the Company solicited and received sufficient consents from the holders of the 2015 Notes to amend certain provisions of the indenture governing the 2015 Notes (the "2015 Notes Indenture") that would eliminate substantially all of the restrictive covenants, certain events of default and other provisions included in the Indenture. On July 31, 2013, the Company entered into a supplemental indenture with the trustee for the 2015 Notes, giving effect to the proposed amendments to the 2015 Notes Indenture and eliminating substantially all of the restrictive covenants and certain default provisions contained in the 2015 Notes Indenture.

On July 31, 2013, the Company satisfied and discharged its obligations under the 2015 Notes Indenture by depositing with the trustee approximately $107.8 million from proceeds received under the Term Loan B Facility. On August 19, 2013, the trustee paid all remaining outstanding 2015 Notes at a redemption price equal to $1,051.25 cash for each $1,000.00 of the principal amount plus accrued and unpaid interest as of such date.

Issuance of 8.875% Senior Notes due 2021

Subsequent to December 31, 2013, the Company issued $200.0 million aggregate principal amount of 8.875% Senior Notes due 2021 (the "2021 Notes") (see Note 17 - Subsequent Events).

Loss on Extinguishment of Debt

As a result of the above repurchase and redemption, all outstanding principal and interest amounts under the 2015 Notes were fully satisfied. The accompanying Consolidated Statements of Operations include a loss on extinguishment of debt as follows (in thousands):



	Amount
2015 Note redemption premium	$	12,162
Write-off of deferred financing costs	3,501
Legal fees and other expenses	235
Loss on extinguishment of debt	$	15,898

Deferred Financing Costs

In connection with Senior Credit Facilities, the Company incurred underwriting fees, agent fees, legal fees and other expenses of $21.9 million that are being amortized over the terms of the Senior Credit Facilities.

Future Maturities

The estimated future maturities of the Company's debt as of December 31, 2013, including interest, is as follows (in thousands):



Year Ending December 31,	Amount
2014	$	45,188
2015	43,888
2016	42,588
2017	41,288
2018	39,988
Thereafter	323,979
Total future maturities	$	536,919

Future maturities are calculated based on the terms of the Senior Credit Facility as of December 31, 2013 and do not reflect the change in payments terms in the amendment to the Senior Credit Facility and paydown of debt subsequent to December 31, 2013 (see Note 17 - Subsequent Events).

Interest Expense, net

Interest expense consisted of the following for each of the three years ended December 31, 2013 (in thousands):



	Year ended December 31,
	2013			2012			2011
Revolving Credit Facility	$	873		$	—		$	—
Term Loan Facilities	10,313			—			—
Prior Credit Facility	765			2,675			4,371
2015 Notes	13,960			23,063			23,063
Amortization of deferred financing costs	2,259			1,261			1,055
Expense allocated to discontinued operations	41			(761		)	(2,764		)
Other, net	(15		)	(171		)	(183		)
Interest expense, net	$	28,197		$	26,067		$	25,542

The weighted average interest rate on the Company's short-term borrowings under its revolving credit facilities during the years ended December 31, 2013 and 2012 was 5.43% and 4.69%, respectively.

COMMITMENTS AND CONTINGENCIES

12 Months Ended

Dec. 31, 2013

COMMITMENTS AND CONTINGENCIES [Abstract]

Commitments and Contingencies

COMMITMENTS AND CONTINGENCIES

Legal Proceedings

United States Attorney's Office for the Southern District of New York and New York State Attorney General investigation

Settlement Agreements with the United States of America, qui tam relator and thirty-five states

Effective January 8, 2014, the Company entered into the Federal Settlement Agreement with the DOJ and David M. Kester (the “Relator”). The Federal Settlement Agreement memorialized the federal and private component of the Company's previously disclosed agreement in principle, first announced on December 16, 2013, to settle all civil claims under the False Claims Act and related statutes and all common law claims (collectively, the “Claims”) that could have been brought by the DOJ and Relator in the Civil Action (as defined below) relating to the distribution of the Medication by the Company's legacy specialty pharmacy division that was divested in May 2012 (the “Legacy Division”). Effective February 11, 2014, the Company entered into the State Settlement Agreements with the Settling States. The State Settlement Agreements memorialized the state component of the Company's previously disclosed agreement in principle, first announced on December 16, 2013, to settle the Claims that could have been brought by the Settling States that arose out of the Legacy Division's distribution of the Medication.

As previously disclosed in September 2013, the Company has cooperated with the United States Attorney’s Office (the “USAO”) for the Southern District of New York (the “SDNY”) and the New York State Attorney General's Medicaid Fraud Control Unit (the "NYMFCU" and together with the USAO, the "Government") by producing documents and information regarding the Legacy Division’s distribution of the Medication. As reflected in the Federal Settlement Agreement, the Company was informed by the Government for the first time in September 2013 that the Government was contemplating claims against the Company relating to the Legacy Division’s distribution of the Medication. Thereafter, and in connection with confidential settlement discussions with the Government, the Company was first informed confidentially that the Company and others were named as defendants in a sealed qui tam lawsuit (a whistleblower action brought by a private citizen, the Relator, on behalf of the government) filed in the SDNY by the Relator, in a case titled United States of America, et al., ex. Rel Kester v. Novartis Pharmaceuticals Corporation, et al, Civil Action No. 11-CIV-8196 (the “Civil Action”) regarding the Legacy Division’s distribution of the Medication and alleging violations of the False Claims Act and related statutes. Until January 8, 2014, the Company was prohibited from publicly disclosing any information related to the existence of the Civil Action. On January 8, 2014, the Civil Action was unsealed and made public on order of the court.

With the execution of the Settlement Agreements, the Company expects the Civil Action to be fully resolved, and the Company expects to be fully resolved the federal and state claims that were or could have been raised in the Civil Action. The Company anticipates that all state claims that have been or could be brought against it in the Civil Action will be dismissed with prejudice. The State Settlement Agreements expressly recognize and affirmatively provide that, by entering into the State Settlement Agreements, the Company has not made any admission of liability and the Company expressly denies the allegations in the Civil Action.

As a part of the State Settlement Agreements, the Company has also resolved any and all claims that the Settling States or their representatives, including the National Association of Medicaid Fraud Control Units (the “NAMFCU”) (which represented the offices of the Attorneys General of the Settling States), could bring for attorney’s fees, investigative fees and/or administrative costs related to the Civil Action. Except for potential claims for certain investigative/administrative costs and attorney’s fees related to the Civil Action incurred by the DOJ, Relator and the NAMFCU that the Company expects not to exceed $0.75 million in the aggregate, the Company does not anticipate any further claims relating to the matters involved in the Settlement Agreements. The Settlement Agreements do not, however, preclude the OIG or any state from taking any administrative actions.

Under the Settlement Agreements, the Company will pay an aggregate of $15.0 million, plus interest (at an annual rate of 3.25%) in three approximately annual payments from January 2014 through January 2016. The Settlement Agreements represented a compromise to avoid the costs, distraction and uncertainty of protracted litigation. The Settlement Agreements do not include any admission of wrongdoing, illegal activity, or liability by the Company or its employees, directors, officers or agents. The lenders under the Company's Senior Credit Facilities provided their consent to the Settlement Agreements. In connection with this consent, the Company paid the lenders an amount of $0.5 million.

During the year ended December 31, 2013, the Company included in its results of discontinued operations an accrual of $15.0 million in connection with the government’s investigation regarding certain operations of the Legacy Division.

Securities Class Action Litigation in the Southern District of New York

On September 30, 2013, a putative securities class action lawsuit was filed against the Company and certain of its officers on behalf of the putative class of purchasers of our securities between August 8, 2011 and September 20, 2013, inclusive. The lawsuit seeks damages and other relief for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Rule 10b-5 promulgated thereunder.

On November 15, 2013, a putative securities class action lawsuit was filed against the Company and certain of its directors and officers and certain underwriters in the Company's April 2013 underwritten public offering of its common stock, on behalf of the putative class of purchasers of our securities between August 8, 2011 and September 23, 2013, inclusive. The lawsuit seeks damages and other relief for alleged violations of Sections 11, 12(a)(2) and 15 of the Securities Act and Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder.

The two class action lawsuits were consolidated and a lead plaintiff was appointed on December 19, 2013. The Company denies any allegations of wrongdoing in the consolidated class action lawsuit. The lead plaintiff filed a consolidated complaint on February 19, 2014 against the Company, certain of its directors and officers, certain underwriters in the Company's April 2013 underwritten public offering of its common stock, and a certain stockholder of the Company. The consolidated complaint is brought on behalf of a putative class of purchasers of the Company's securities between November 9, 2012 and November 6, 2013, inclusive, and persons and entities who purchased the Company's securities pursuant or traceable to two underwritten public offerings of the Company’s common stock conducted in April 2013, and August 2013. The consolidated complaint alleges generally that the defendants made material misstatements and/or failed to disclose matters related the Legacy Division’s distribution of the Medication as well as the Company’s PBM Services segment. The consolidated complaint asserts claims under Sections 11, 12(a)(2) and 15 of the Securities Act and Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder. The Company intends to file a motion to dismiss the consolidated complaint. Pursuant to the parties' scheduling order, briefing on the motion to dismiss will be complete in July 2014. The Company believes all of the claims in these class action lawsuits are without merit and intends to vigorously defend against these claims. However, there is no assurance that the Company will be successful in its defense or that insurance will be available or adequate to fund any settlement or judgment or the litigation costs of these actions. Additional similar lawsuits may be filed. Moreover, the Company is not able to predict the outcome or reasonably estimate a range of possible loss at this time.

Professional Home Care Services Litigation

On March 31, 2009, Professional Home Care Services, Inc., or PHCS, which is one of the subsidiaries we acquired through our acquisition of CHS, was sued by Alexander Infusion, LLC, a New York-based home infusion company, in the Supreme Court of the State of New York. The complaint alleges principally breach of contract arising in connection with PHCS's failure to consummate an acquisition of Alexander Infusion after failing to satisfy the conditions to PHCS's obligation to close. Alexander Infusion has sued for $3.5 million in damages. We believe Alexander Infusion's claims to be without merit and intend to continue to defend against the allegations vigorously. Furthermore, under the Merger Agreement, subject to certain limits, the former CHS Stockholders agreed to indemnify us in connection with any losses arising from claims made in respect of the acquisition agreement entered into between PHCS and Alexander Infusion.

Legal Settlements

Following responses to government subpoenas and discussions with the government, in May 2011 we were advised of a qui tam lawsuit filed under seal in federal court in Minnesota in 2006 and naming us as defendant. The complaint alleged violations of healthcare statutes and regulations by the Company and predecessor companies dating back to 2000. The Company entered into a final settlement under which we paid the states $0.6 million and the federal government $4.4 million resolving all issues alleged in the complaint and the government's investigation in exchange for a release and dismissal of the claims. A related qui tam relator's employment termination claim and her lawyer's statutory legal fee claim were also resolved. During the year ended December 31, 2011, the Company recorded a legal settlement expense of $4.8 million related to the settlement. During the year ended December 31, 2012, the Company recorded additional legal settlement expense of $0.8 million to account for the final settlement amount. The legal settlement expenses were included in income from discontinued operations, net of income taxes in the accompanying Consolidated Statements of Operations.

Government Regulation

Various federal and state laws and regulations affecting the healthcare industry do or may impact the Company's current and planned operations, including, without limitation, federal and state laws prohibiting kickbacks in government health programs, federal and state antitrust and drug distribution laws, and a wide variety of consumer protection, insurance and other state laws and regulations. While management believes the Company is in substantial compliance with all existing laws and regulations material to the operation of its business, such laws and regulations are subject to rapid change and often are uncertain in their application. As controversies continue to arise in the healthcare industry (for example, the efforts of Plan Sponsors and pharmacy benefit managers to limit formularies, alter drug choice and establish limited networks of participating pharmacies), federal and state regulation and enforcement priorities in this area can be expected to increase, the impact of which cannot be predicted.

From time to time, the Company responds to subpoenas and requests for information from governmental agencies. The Company cannot predict with certainty what the outcome of any of the foregoing might be. While the Company believes it is in substantial compliance with all laws, rules and regulations that affects its business and operations, there can be no assurance that the Company will not be subject to scrutiny or challenge under one or more existing laws or that any such challenge would not be successful. Any such challenge, whether or not successful, could have a material effect upon the Company's Consolidated Financial Statements. A violation of the Federal anti-kickback statute, for example, may result in substantial criminal penalties, as well as suspension or exclusion from the Medicare and Medicaid programs. Moreover, the costs and expenses associated with defending these actions, even where successful, can be significant. Further, there can be no assurance the Company will be able to obtain or maintain any of the regulatory approvals that may be required to operate its business, and the failure to do so could have a material effect on the Company's Consolidated Financial Statements.

Leases

The Company leases its facilities and certain equipment under various operating leases with third parties. The majority of these leases contain escalation clauses that increase base rent payments based upon either the Consumer Price Index or an agreed upon schedule.

In addition, the Company utilizes capital leases agreements with third parties to obtain certain assets such as telecommunications equipment and vehicles. Interest rates on capital leases are both fixed and variable and range from 3% to 7%.

As of December 31, 2013, future minimum lease payments under operating and capital leases were as follows (in thousands):



	Operating Leases		Capital Leases		Total
2014	$	9,622	$	333	$	9,955
2015	7,771		438		8,209
2016	6,202		201		6,403
2017	5,038		39		5,077
2018	3,242		1		3,243
2019 and thereafter	3,177		—		3,177
Total	$	35,052	$	1,012	$	36,064

Rent expense for leased facilities and equipment was approximately $7.9 million, $6.2 million and $6.3 million for the years ended December 31, 2013, 2012 and 2011, respectively.

Purchase Commitments

As of December 31, 2013, the Company had commitments to purchase prescription drugs from drug manufacturers of approximately $37.3 million in 2014. These purchase commitments are made at levels expected to be used in the normal course of business.

OPERATING AND REPORTABLE SEGMENTS

12 Months Ended

Dec. 31, 2013

OPERATING AND REPORTABLE SEGMENTS [Abstract]

Operating and Reportable Segments

OPERATING AND REPORTABLE SEGMENTS

On February 1, 2012, the Company divested its traditional and specialty pharmacy mail operations and community retail pharmacy stores, as a result the Company reevaluated its operating and reportable segments in accordance with the provisions of ASC 280 Segment Reporting (“ASC 280”). Based on this review, the Company changed its operating and reportable segments from “Infusion/Home Health Services” and “Pharmacy Services” to its new operating and reportable segments: “Infusion Services", "Home Health Services” and “PBM Services”. These three operating and reportable segments reflect how the Company's chief operating decision maker reviews the Company's results in terms of allocating resources and assessing performance. Disclosures for the year ended December 31, 2011 reflect the change in reportable segments.

The Infusion Services operating and reportable segment provides services consisting of home infusion therapy, respiratory therapy and the provision of durable medical equipment, products and services. Infusion services include the dispensing and administering of infusion-based drugs, which typically require nursing support and clinical management services, equipment to administer the correct dosage and patient training designed to improve patient outcomes.

The Home Health Services operating and reportable segment provides services including the provision of skilled nursing services and therapy visits, private duty nursing services, hospice services, rehabilitation services and medical social services to patients primarily in their home.

The PBM Services operating and reportable segment consists of PBM services, which primarily consists of discount card programs. The discount card programs provide a cost effective alternative for individuals who may be uninsured, underinsured or may have restrictive coverage that disallows reimbursement for certain medications. Under these discount programs, individuals who present a discount card at one of the Company's participating network pharmacies receive prescription medications at a discounted price compared to the retail price. In addition, in the Company's capacity as a pharmacy benefit manager, it has fully funded prescription benefit programs where the Company reimburses its network pharmacies and third party payors in turn reimburse the Company based on Medi-Span reported pricing for those claims fulfilled for their plan participants.

The Company's chief operating decision maker evaluates segment performance and allocates resources based on Segment Adjusted EBITDA. Segment Adjusted EBITDA is defined as income (loss) from continuing operations, net of income taxes adjusted for net interest expense, income tax expense (benefit), depreciation, amortization of intangibles and stock-based compensation expense and prior to the allocation of certain corporate expenses. Segment Adjusted EBITDA excludes acquisition and integration expenses; restructuring and other expense; and other expenses related to the Company's strategic assessment. Segment Adjusted EBITDA is a measure of earnings that management monitors as an important indicator of operating and financial performance. The accounting policies of the operating and reportable segments are consistent with those described in the Company's summary of significant accounting policies.

Segment Reporting Information

(in thousands)



	Year Ended December 31,
	2013			2012			2011
Results of Operations:
Revenue:
Infusion Services - product revenue	$	675,684		$	471,506		$	365,526
Infusion Services - service revenue	21,643			10,080			8,756
Total Infusion Services revenue	697,327			481,586			374,282
Home Health Services - service revenue	72,276			69,190			69,635
PBM Services - service revenue	72,592			111,861			110,589
Total revenue	$	842,195		$	662,637		$	554,506

Adjusted EBITDA by Segment before corporate overhead:
Infusion Services	$	60,677		$	36,764		$	35,128
Home Health Services	2,884			5,401			5,954
PBM Services	17,110			25,659			30,122
Total Segment Adjusted EBITDA	80,671			67,824			71,204
Corporate overhead	(32,042		)	(26,755		)	(23,308		)
Interest expense, net	(28,197		)	(26,067		)	(25,542		)
Loss on extinguishment of debt	(15,898		)	—			—
Income tax benefit (expense)	(2,538		)	4,439			(435		)
Depreciation	(13,555		)	(8,513		)	(6,591		)
Amortization of intangibles	(6,671		)	(3,957		)	(3,376		)
Stock-based compensation expense	(9,450		)	(6,122		)	(4,467		)
Acquisition and integration expenses	(16,130		)	(4,046		)	—
Restructuring and other expenses and investments	(9,796		)	(5,143		)	(7,909		)
Loss from continuing operations, net of income taxes	$	(53,606	)	$	(8,340	)	$	(424	)



	Year Ended December 31,
	2013		2012		2011
Supplemental Operating Data:
Capital Expenditures:
Infusion Services	$	15,972	$	6,685	$	4,826
Home Health Services	69		171		170
PBM Services	—		—		—
Corporate unallocated	9,576		4,130		2,857
Total Capital Expenditures	$	25,617	$	10,986	$	7,853

Depreciation Expense:
Infusion Services	$	8,640	$	4,347	$	5,242
Home Health Services	75		111		48
PBM Services	—		—		—
Corporate unallocated	4,840		4,055		1,301
Total Depreciation Expense	$	13,555	$	8,513	$	6,591

Total Assets:
Infusion Services	$	794,006	$	438,623	$	353,999
Home Health Services	64,428		62,403		64,672
PBM Services	25,239		36,354		40,418
Corporate unallocated	53,169		95,813		24,348
Assets from discontinued operations	—		—		59,005
Assets associated with discontinued operations, not sold	16		9,183		134,660
Total Assets	$	936,858	$	642,376	$	677,102

Goodwill:
Infusion Services	$	558,593	$	304,282	$	265,859
Home Health Services	33,784		33,784		33,784
PBM Services	12,744		12,744		12,744
Total Goodwill	$	605,121	$	350,810	$	312,387

Subsequent to December 31, 2013, the Company entered into a Stock Purchase Agreement to sell substantially all of the assets and entities that make up its Home Health Services segment (see Note 17 - Subsequent Events).

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

+ Details

CONCENTRATION OF RISK	12 Months Ended
CONCENTRATION OF RISK	Dec. 31, 2013
Risks and Uncertainties [Abstract]
Concentration of Risk	CONCENTRATION OF RISK Customer and Credit Risk The Company provides trade credit to its customers in the normal course of business. One payor, UnitedHealthcare, accounted for approximately 21%, 18% and 13% of revenue during the years ended December 31, 2013, 2012 and 2011, respectively. The majority of the revenue is related to the Infusion Services segment. Therapy Revenue Risk The Company sells products related to the Immune Globulin (IG) therapy, which represented 18%, 19%, and 25% of revenue during the years ended December 31, 2013, 2012 and 2011, respectively. The revenue is related to the Infusion Services segment.

INCOME TAXES

12 Months Ended

Dec. 31, 2013

Income Tax Disclosure [Abstract]

Income Taxes

INCOME TAXES

The Company’s federal and state income tax expense (benefit) is summarized in the following table (in thousands):



	Year Ended December 31,
	2013			2012			2011
Current
Federal	$	(866	)	$	(3,759	)	$	(167	)
State	(1,412		)	(676		)	(122		)
Total current	(2,278		)	(4,435		)	(289		)
Deferred
Federal	4,437			121			632
State	379			(125		)	92
Total deferred	4,816			(4		)	724
Total tax (benefit) provision	$	2,538		$	(4,439	)	$	435

The effect of temporary differences that give rise to a significant portion of deferred taxes is as follows (in thousands):



	December 31,
	2013			2012
Deferred tax assets:
Reserves not currently deductible	$	10,315		$	11,771
Net operating loss carryforwards	39,556			16,287
Goodwill and intangibles (tax deductible)	8,089			7,278
Accrued expenses	148			3,055
Stock based compensation	6,277			3,717
Other	417			1,778
Total deferred tax assets	64,802			43,886
Deferred tax liabilities:
Property basis differences	(506		)	(3,144		)
Indefinite-lived goodwill and intangibles	(16,122		)	(11,306		)
Less: valuation allowance	(63,281		)	(39,727		)
Net deferred tax liability	$	(15,107	)	$	(10,291	)

During the fourth quarter of 2010, the Company concluded that it was more likely than not that its deferred tax assets would not be realized. The Company continually assesses the necessity of a valuation allowance. Based on this assessment, the Company concluded that a valuation allowance, in the amount of $63.3 million and $39.7 million, was required as of December 31, 2013 and 2012, respectively. If the Company determines in a future period that it is more likely than not that part or all of the deferred tax assets will be realized, the Company will reverse part or all of the valuation allowance.

At December 31, 2013, the Company had federal net operating loss (“NOL”) carryforwards of approximately $112.0 million, of which $23.9 million is subject to an annual limitation, which will begin expiring in 2026 and later. Of the Company’s $112.0 million of federal NOLs, $17.9 million will be recorded in additional paid-in capital when realized as these NOLs are related to the exercise of non-qualified stock options and restricted stock grants. The Company has post-apportioned state NOL carryforwards of approximately $138.4 million, the majority of which will begin expiring in 2017 and later.

The Company’s reconciliation of the statutory rate to the effective income tax rate is as follows (in thousands):



	Year Ended December 31,
	2013			2012			2011
Tax (benefit) provision at statutory rate	$	(17,874	)	$	(4,473	)	$	4
State tax (benefit) provision, net of federal taxes	(2,419		)	(587		)	36
Non-deductible transaction costs	317			—			—
Penalties	—			—			78
Change in tax contingencies	(1,157		)	(633		)	(675		)
Valuation allowance changes affecting income tax expense	23,493			1,104			778
Other	178			150			214
Tax (benefit) provision	$	2,538		$	(4,439	)	$	435

As of December 31, 2013, the Company had $1.2 million of gross unrecognized tax benefits, of which $0.2 million, if recognized, would favorably affect the effective income tax rate in future periods. A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):



	Year Ended December 31,
	2013			2012			2011
Unrecognized tax benefits balance at January 1,	$	2,754		$	2,605		$	2,869
Gross increases for tax positions of prior years	—			—			—
Gross increases for tax positions taken in current year	—			636			378
Settlements with taxing authorities	—			—			(212		)
Lapse of statute of limitations	(1,582		)	(487		)	(430		)
Unrecognized tax benefits balance at December 31,	$	1,172		$	2,754		$	2,605

The Company's policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of income tax expense in the Consolidated Statements of Operations. As of December 31, 2013 and 2012, the Company had approximately $0.1 million and $0.3 million of accrued interest related to uncertain tax positions, respectively.

The Company files income tax returns, including returns for its subsidiaries, with federal, state and local jurisdictions. The Company's uncertain tax positions are related to tax years that remain subject to examination. As of December 31, 2013, U.S. tax returns for the years 2011 through 2013 remain subject to examination by federal tax authorities. Tax returns for the years 2009 through 2013 remain subject to examination by state and local tax authorities for a majority of the Company's state and local filings.

STOCK-BASED COMPENSATION

12 Months Ended

Dec. 31, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation

STOCK-BASED COMPENSATION

BioScrip Equity Incentive Plans

Under the Company's Amended and Restated 2008 Equity Incentive Plan as amended and restated (the “2008 Plan”), the Company may issue, among other things, incentive stock options (“ISOs”), non-qualified stock options (“NQSOs”), stock appreciation rights ("SARs"), restricted stock, performance shares and performance units to employees and directors. While SARS are authorized under the 2008 Plan, they may also be issued outside of the plan. Under the 2008 Plan, 3,580,000 shares were originally authorized for issuance (subject to adjustment for grants made under the Company's 2001 Incentive Stock Plan (the “2001 Plan”) after January 1, 2008, as well as for forfeitures, expirations or awards that under the 2001 Plan otherwise settled in cash after the adoption thereof). Upon the effective date of the 2008 Plan, the Company ceased making grants under the 2001 Plan. The 2008 Plan is administered by the Company's Management Development and Compensation Committee (the “Compensation Committee”), a standing committee of the Board of Directors. On June 10, 2010, the Company's stockholders approved an amendment to the 2008 Plan to increase the number of authorized shares of common stock available for issuance by 3,275,000 shares to 6,855,000 shares. On May 7, 2013, the Company's stockholders approved an amendment to the 2008 Plan to increase by 300,000 shares (from 500,000 to 800,000) the aggregate number of shares within the 2008 Plan that may be granted to directors.

As of December 31, 2013, there were 971,658 shares that remained available for grant under the 2008 Plan.

BioScrip/CHS Equity Plan

Effective upon closing of the acquisition of CHS, the CHS 2006 Equity Incentive Plan was adopted by the Company and renamed the “BioScrip/CHS 2006 Equity Incentive Plan” (as amended and restated, the “BioScrip/CHS Plan” and together with the 2008 Plan, the "Equity Compensation Plans"). There were 13,000,000 shares of CHS common stock originally authorized for issuance under the CHS 2006 Equity Incentive Plan, which were converted into 3,106,315 shares of BioScrip common stock using the exchange ratio defined by the merger agreement. The Board of Directors further amended the BioScrip/CHS Plan to provide for it to have substantially the same terms and provisions as the 2008 Plan.

Of the options authorized and outstanding under the BioScrip/CHS Plan on the date of the acquisition, 716,086 options were designated as “rollover” options. These rollover options were issued to the top five executives of CHS at the time of the acquisition, and otherwise remain subject to the terms of the BioScrip/CHS Plan, as amended, and fully vested on the date of conversion. Under the terms of the BioScrip/CHS Plan, any shares of the Company's common stock subject to rollover options that expire or otherwise terminate before all or any part of the shares subject to such options have been purchased as a result of the exercise of such options shall become available for issuance under the BioScrip/CHS Plan.

The remaining 2,390,229 shares are authorized for issuance under the BioScrip/CHS Plan. These shares may be used for awards under the BioScrip/CHS Plan, provided that awards using such available shares are not made after the original expiration date of the pre-existing plan, and are only made to individuals who were not employees or directors of the Company or an affiliate or subsidiary of the Company prior to such acquisition. As of December 31, 2013, there were 800,361 shares that remained available under the BioScrip/CHS Plan.

Annual Equity Grants

During the year ended December 31, 2013, the Compensation Committee approved grants of approximately 1.9 million NQSO awards and 0.4 million restricted stock awards to key employees and members of the board of directors consistent with the Compensation Committee's historic grant practices.

Stock Options

Options granted under the Equity Compensation Plans: (a) typically vest over a three-year period and, in certain instances, fully vest upon a change in control of the Company, (b) have an exercise price that may not be less than 100% of its fair market value on the date of grant and (c) are generally exercisable for ten years after the date of grant, subject to earlier termination in certain circumstances.

Option expense is amortized on a straight-line basis over the requisite service period. The Company recognized compensation expense related to stock options of $6.0 million, $4.6 million, and $3.7 million, in the years ended December 31, 2013, 2012 and 2011, respectively.

The weighted-average, grant-date fair value of options granted during the years ending December 31, 2013, 2012 and 2011 was $6.24, $4.00, and $2.53, respectively. A binomial lattice-based valuation model is used to estimate the fair value of each option granted. Because of the limitations with closed-form valuation models, such as the Black-Scholes model, we have determined that this more flexible binomial model provides a better estimate of the fair value of our options. The fair value of each stock option award on the date of the grant was calculated using the following weighted-average assumptions:



	2013			2012			2011
Expected volatility	61.8		%	64.8		%	64.1		%
Risk-free interest rate	2.13		%	1.98		%	3.23		%
Expected life of options	5.5 years			5.8 years			5.2 years
Dividend rate	—			—			—
Fair value of options	$	6.24		$	4.00		$	2.53

Stock option activity for the Equity Compensation Plans through December 31, 2013 was as follows:



	Options		Weighted Average Exercise Price		Aggregate Intrinsic Value (thousands)		Weighted Average Remaining Contractual Life
Balance at December 31, 2012	4,885,215		$	5.97	$	23,463	7.8 years
Granted	1,928,500		$	11.25
Exercised	(517,979	)	$	4.83
Forfeited and expired	(562,915	)	$	8.57
Balance at December 31, 2013	5,732,821		$	7.59	$	6,185	7.7 years
Outstanding options less expected forfeitures at December 31, 2013	5,274,974		$	7.44	$	5,936	7.6 years
Exercisable at December 31, 2013	2,492,009		$	5.84	$	4,362	6.4 years

Cash received from option exercises under share-based payment arrangements for the years ended December 31, 2013, 2012, and 2011 was $2.5 million, $8.6 million, and $3.2 million, respectively.

The maximum term of stock options under these plans is ten years. Options outstanding as of December 31, 2013 expire on various dates ranging from May 2014 through November 2023. The following table outlines our outstanding and exercisable stock options as of December 31, 2013:



	Options Outstanding				Options Exercisable
Range of Option Exercise Price	Outstanding Options	Weighted Average Exercise Price		Weighted Average Remaining Contractual Life	Options Exercisable	Weighted Average Exercise Price
$1.71 - $4.24	443,516	$	2.83	5.2 years	411,850	$	2.72
$4.42 - $6.61	1,104,875	$	5.03	6.5 years	768,053	$	5.13
$6.62- $6.65	1,856,582	$	6.63	7.8 years	879,922	$	6.63
$6.67 - $9.16	857,348	$	7.90	7.9 years	432,184	$	8.44
$11.04 - $16.63	1,470,500	$	12.01	9.2 years	—	$	—
All options	5,732,821	$	7.59	7.7 years	2,492,009	$	5.84

As of December 31, 2012 and 2011 the exercisable portion of outstanding options was approximately 1.9 million shares and 3.3 million shares, respectively.

As of December 31, 2013 there was $13.1 million of unrecognized compensation expense related to unvested option grants that is expected to be recognized over a weighted-average period of 2.0 years. The total intrinsic value of options exercised during the years December 31, 2013, 2012 and 2011 was $3.8 million, $4.4 million, and $2.5 million, respectively.

As compensation expense for options granted is recorded over the requisite service period of options, future stock-based compensation expense may be greater as additional options are granted.

Restricted Stock

Under the Equity Compensation Plans, stock grants subject solely to an employee’s or director’s continued service with the Company will not become fully vested less than (a) three years from the date of grant to employees and, in certain instances, may fully vest upon a change in control of the Company, and (b) one year from the date of grant for directors. Stock grants subject to the achievement of performance conditions will not vest less than one year from the date of grant. Such performance shares may vest after one year from grant. No such time restrictions applied to stock grants made under the Company’s prior equity compensation plans.

The Company recognized compensation expense related to restricted stock awards of $3.5 million, $0.4 million, and $0.5 million for the years ended December 31, 2013, 2012 and 2011, respectively.

Since the Company records compensation expense for restricted stock awards based on the vesting requirements, which generally includes time elapsed, market conditions and/or performance conditions, the weighted average period over which the expense is recognized varies. Also, future equity-based compensation expense may be greater if additional restricted stock awards are made.

Each share of restricted stock issued reduces the number of shares available for grant under the Equity Compensation Plans by 1.53 shares.

Restricted stock award activity through December 31, 2013 was as follows:



	Restricted Stock		Weighted Average Award Date Fair Value		Weighted Average Remaining Recognition Period
Balance at December 31, 2012	70,000		$	7.52	0.4 years
Granted	370,000		$	12.31
Awards Vested	(70,000	)	$	7.52
Canceled	—		$	—
Balance at December 31, 2013	370,000		$	12.31	0.3 years

As of December 31, 2013, there was $1.2 million of unrecognized compensation expense related to unvested restricted stock awards. That expense is expected to be recognized over a weighted average period of 0.3 years. The total grant date fair market value of awards vested during the years ended December 31, 2013, 2012and 2011 was $0.5 million, $0.8 million, and $0.6 million, respectively. The total intrinsic value of restricted stock awards vested during the years December 31, 2013, 2012 and 2011 was $0.5 million, $2.3 million, and $0.5 million, respectively.

Performance Units

Under the 2008 Plan, the Compensation Committee may grant performance units to key employees. The Compensation Committee will establish the terms and conditions of any performance units granted, including the performance goals, the performance period and the value for each performance unit. If the performance goals are satisfied, the Company would pay the key employee an amount in cash equal to the value of each performance unit at the time of payment. In no event may a key employee receive an amount in excess of $1.0 million with respect to performance units for any given year. As of December 31, 2013, no performance units have been granted under the 2008 Plan.

Stock Appreciation Rights

The Company has granted and has outstanding cash-based phantom stock appreciation rights ("SARs), which are independent of the Company's 2008 Equity Incentive Plan, with respect to 330,000 shares of the Company's common stock. The SARs vest in three equal annual installments and will fully vest in connection with a change of control (as defined in the grantee's employment agreement). The SARs may be exercised, in whole or in part, to the extent each SAR has been vested and will receive in cash the amount by which the closing stock price on the exercise date exceeds the Grant Price, if any. Upon the exercise of any SARs, as soon as practicable under the applicable federal and state securities laws, the grantee may be required to use the net after-tax proceeds of such exercise to purchase shares of the Common Stock from the Company at the closing stock price of the Common Stock on that date and hold such shares of Common Stock for a period of not less than one year from the date of purchase, except that the grantee will not be required to purchase any shares of Common Stock if the SAR is exercised on or after a change of control of the Company. The grantee's right to exercise the SAR will expire on the earliest of (1) the tenth anniversary of the grant date, or (2) under certain conditions as a result of termination of the grantee's employment.

SAR activity through December 31, 2013 was as follows:



	Stock Appreciation Right		Weighted Average Exercise Price		Weighted Average Remaining Recognition Period
Balance at December 31, 2012	380,000		$	6.72	1.8 years
Granted	—		$	—
Exercised	—		$	—
Canceled	(50,000	)	$	6.67
Balance at December 31, 2013	330,000		$	6.73	1.7 years

The SARs are recorded as a liability in other non-current liabilities in the accompanying Consolidated Balance Sheets. Compensation expense related to the SARs for the year ended December 31, 2013, 2012 and 2011 was $0.0 million, $1.1 million and $0.3 million As of December 31, 2013 there was $0.3 million of unrecognized compensation expense related to the SARs that is expected to be recognized over a weighted-average period of 1.7 years. In addition, because they are settled with cash, the fair value of the SAR awards is revalued on a quarterly basis. During the years ended December 31, 2013, 2012 and 2011 the Company paid $0.0 million, $0.3 million and $0.0 million related to the exercise of SAR awards.

Employee Stock Purchase Plan

On May 7, 2013, the Company's stockholders approved the BioScrip, Inc. Employee Stock Purchase Plan (the “ESPP”). The ESPP provides all eligible employees, as defined under the ESPP, the opportunity to purchase up to a maximum number of shares of Common Stock of the Company as determined by the Compensation Committee. Participants in the ESPP may acquire the Common Stock at a cost of 85% of the lower of the fair market value on the first or last day of the Plan Year from January 1st through December 31st. The Company has filed a Registration Statement on Form S-8 to register 750,000 shares of Common Stock for issuance under the ESPP. As of December 31, 2013, no shares have been issued and no expense has been incurred under the ESPP.

DEFINED CONTRIBUTION PLAN	12 Months Ended
DEFINED CONTRIBUTION PLAN	Dec. 31, 2013
Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]
Defined Contribution Plan	DEFINED CONTRIBUTION PLAN The Company maintains a deferred compensation plan under Section 401(k) of the Internal Revenue Code. Under the Plan, employees may elect to defer up to 100% of their salary, subject to Internal Revenue Service limits, and the Company may make a discretionary matching contribution. The Company recorded matching contributions in selling, general and administrative expenses in the Consolidated Statements of Operations of $0.5 million during the year ended December 31, 2013. The Company elected not to make matching contributions during the years ended December 31, 2012 and 2011.

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)

12 Months Ended

Dec. 31, 2013

Quarterly Financial Information Disclosure [Abstract]

Selected Quarterly Financial Data (Unaudited)

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)

A summary of unaudited quarterly financial information for the years ended December 31, 2013 and 2012 is as follows (in thousands except per share data):



	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
Year ended December 31, 2013
Revenue	$	199,071		$	190,733		$	208,879		$	243,512
Gross profit	$	63,237		$	65,012		$	68,682		$	74,883
Net loss from continuing operations	$	(7,470	)	$	(8,317	)	$	(22,442	)	$	(15,377	)
Net (loss) income from discontinued operations	$	(658	)	$	(563	)	$	(11,645	)	$	(3,182	)
Net (loss) income	$	(8,128	)	$	(8,880	)	$	(34,087	)	$	(18,559	)

Loss per share from continuing operations, basic and diluted	$	(0.13	)	$	(0.13	)	$	(0.35	)	$	(0.22	)
Loss per share from discontinued operations, basic and diluted	(0.01		)	(0.01		)	(0.18		)	(0.05		)
Loss income per share, basic and diluted	$	(0.14	)	$	(0.14	)	$	(0.53	)	$	(0.27	)

Year ended December 31, 2012
Revenue	$	155,633		$	155,901		$	170,365		$	180,738
Gross profit	$	53,522		$	53,041		$	58,004		$	60,393
Net (loss) income from continuing operations	$	(2,023	)	$	(4,293	)	$	(605	)	$	(1,419	)
Net income (loss) from discontinued operations	$	(680	)	$	76,059		$	(10,931	)	$	8,599
Net income (loss)	$	(2,703	)	$	71,766		$	(11,536	)	$	7,180

Loss per share from continuing operations, basic and diluted	$	(0.04	)	$	(0.07	)	$	(0.01	)	$	(0.03	)
Loss per share from discontinued operations, basic and diluted	(0.01		)	1.35			(0.19		)	0.15
Loss income per share, basic and diluted	$	(0.05	)	$	1.28		$	(0.20	)	$	0.12

SUBSEQUENT EVENTS	12 Months Ended
SUBSEQUENT EVENTS	Dec. 31, 2013
Subsequent Events [Abstract]
Subsequent Events	SUBSEQUENT EVENTS Second Amendment to Senior Credit Facilities On January 31, 2014, the Company entered into the Second Amendment to the Senior Credit Facilities, which, among other things (i) provides additional flexibility with respect to compliance with the maximum net leverage ratio for the fiscal quarters ending December 31, 2013 through and including December 31, 2014, (ii) provides additional flexibility under the indebtedness covenants to permit the Company to obtain up to $150.0 million of second-lien debt and issue up to $250.0 million of unsecured bonds, provided that 100% of the net proceeds are applied first to the Revolving Credit Facility, with no corresponding permanent commitment reduction, and then to the Term Loan B Facility, (iii) provides the requisite flexibility to sell non-core assets, subject to the satisfaction of certain conditions, and (iv) increased the applicable interest rates for the Term Loan Facilities to the Eurodollar rate plus 6.00% or the base rate plus 5.00%, until the occurrence of certain pricing decrease triggering events, as defined in the amendment. Upon the occurrence of a pricing decrease triggering event, the interest rates for the Senior Credit Facilities may revert to the Eurodollar rate plus 5.25% or the base rate plus 4.25%. Stock Purchase Agreement On February 1, 2014, the Company entered into a Stock Purchase Agreement with LHC Group, Inc., a Delaware corporation, and certain of its subsidiaries (collectively, the “Buyers”) wherein the Buyers have agreed to acquire substantially all of the entities and assets that make up the Company’s Home Health Services segment for a total cash purchase price of approximately $60.0 million, subject to a net working capital adjustment. The closing of this transaction is expected to occur on March 31, 2014. The closing of this transaction is subject to customary closing conditions, including compliance with covenants, release and satisfaction of all indebtedness, receipt of certain contractual consents and receipt of certain regulatory approvals. The Stock Purchase Agreement may be terminated at any time prior to the closing date by, among other things, mutual agreement of the Company and Buyers, or by either the Company or the Buyers if the other party fails to satisfy the applicable closing conditions under the Stock Purchase Agreement by July 1, 2014. The Company intends to use the net proceeds from the sale to pay down its debt. The agreement to sell the Home Health Services segment is consistent with the Company’s continuing strategic evaluation of its non-core businesses and its decision to continue to focus growth initiatives and capital in the Infusion Services segment. Issuance of 8.875% Senior Notes due 2021 On February 11, 2014, the Company issued $200.0 million aggregate principal amount of the 2021 Notes. Pursuant to the terms of the Second Amendment to the Senior Credit Facilities, the Company used approximately $194.5 million of the net proceeds of the offering to repay $59.3 million of the Revolving Credit Facility and $135.2 million of the term loan portion of the Senior Credit Facilities. The 2021 Notes are senior unsecured obligations of the Company and are fully and unconditionally guaranteed by certain subsidiaries of the Company. Interest is payable semi-annually on February 1 and August 1. The Company, at its option, may redeem some or all of the 2021 Notes prior to maturity. The 2021 Notes were offered to qualified institutional buyers in reliance on Rule 144A under the Securities Act and outside the United States in reliance on Regulation S under the Securities Act. Registration Rights Agreement In connection with the issuance of the 2021 Notes, the Company entered into a registration rights agreement on February 11, 2014 its subsidiary guarantors of the 2021 Notes and the initial purchasers (the “Registration Rights Agreement”). Pursuant to the Registration Rights Agreement, the Company has agreed to file an exchange offer registration statement to exchange the 2021 Notes for substantially identical notes registered under the Securities Act. The Company has also agreed to file a shelf registration statement to cover resale of the 2021 Notes under certain circumstances.

Schedule II

12 Months Ended

Dec. 31, 2013

Valuation and Qualifying Accounts [Abstract]

Schedule of Valuation and Qualifying Accounts Disclosure

Bioscrip, Inc. and Subsidiaries

Schedule II-- Valuation and Qualifying Accounts

(in thousands)



	Balance at Beginning of Period		Write-Off of Receivables			Charged to Costs and Expenses		Balance at End of Period
Year ended December 31, 2011
Allowance for doubtful accounts	$	16,421	$	(12,347	)	$	18,654	$	22,728
Year ended December 31, 2012
Allowance for doubtful accounts	$	22,728	$	(27,482	)	$	26,966	$	22,212
Year ended December 31, 2013
Allowance for doubtful accounts	$	22,212	$	(23,962	)	$	20,963	$	19,213

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2013

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]

Consolidation, Policy [Policy Text Block]

Consolidation

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

Fair Value Measurement, Policy [Policy Text Block]

Fair Value Measurements


•	Level 1 - Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.


•	Level 2 - Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.


•	Level 3 - Inputs to the fair value measurement are unobservable inputs or valuation techniques.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

Highly liquid investments with a maturity of three months or less when purchased are classified as cash equivalents.

Receivables, Policy [Policy Text Block]

Receivables

Trade and Other Accounts Receivable, Policy [Policy Text Block]

Allowance for Doubtful Accounts



	December 31, 2013				December 31, 2012 ⁽¹⁾
	0 - 180 days	Over 180 days	Total		0 - 180 days	Over 180 days	Total
Government	37,344	9,490	46,834		41,124	2,744	43,868
Commercial	126,498	28,186	154,684		75,389	26,137	101,526
Patient	2,833	2,163	4,996		1,784	4,137	5,921
Gross accounts receivable	166,675	39,839	206,514		118,297	33,018	151,315
Allowance for doubtful accounts			(19,213	)			(22,212	)
Net accounts receivable			187,301				129,103


(1)	The December 31, 2012 balances include the remaining Pharmacy Services gross accounts receivables not sold as part of the 2012 Asset Purchase Agreement of $12.8 million over 180 days and the allowance for doubtful accounts includes $8.0 million related to these receivables. At December 31, 2013, none of the accounts receivable retained by the Company remained.



	December 31, 2013							December 31, 2012
	0 - 180 days		Over 180 days		Total			0 - 180 days		Over 180 days			Total
Gross accounts receivable	$	166,675	$	39,839	$	206,514		$	118,297	$	33,018		$	151,315
Add: acquisition-related allowance	—		5,243		5,243			—		—			—
Less: Pharmacy Services accounts receivable	—		—		—			—		(12,840		)	(12,840		)
Pro forma gross accounts receivable	$	166,675	$	45,082	211,757			$	118,297	$	20,178		138,475
Allowance for doubtful accounts					(19,213		)						(22,212		)
Add: Acquisition-related allowance					(5,243		)						—
Less: Pharmacy Services allowance					—								8,045
Pro forma allowance for doubtful accounts					(24,456		)						(14,167		)
Pro forma net accounts receivable					$	187,301							$	124,308

The pro forma allowance for doubtful accounts as a percent of pro forma accounts receivable was 11.5% and 10.2% at December 31, 2013 and 2012, respectively.

Revenue Recognition, Discounts [Policy Text Block]

Allowance for Contractual Discounts

Inventory, Policy [Policy Text Block]

Inventory

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

Property and equipment is stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of assets as follows:



Asset	Useful Life
Computer hardware and software	3	-	5	years
Office equipment	3	-	5	years
Vehicles	4	-	5	years
Medical equipment	2	-	5	years
Furniture and fixtures			5	years

Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]

Goodwill

Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]

Intangible Assets

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment of Long Lived Assets

Consolidation, Variable Interest Entity, Policy [Policy Text Block]

Variable Interest Entity

Amounts Due to Plan Sponsors Policy [Policy Text Block]

Amounts due to Plan Sponsors

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

Cost of Sales, Policy [Policy Text Block]

Cost of Revenue

Revenue Recognition, Rebates [Policy Text Block]

Rebates

Lease, Policy [Policy Text Block]

Lease Accounting

Income Tax, Policy [Policy Text Block]

Income Taxes

Fair Value of Financial Instruments, Policy [Policy Text Block]

Financial Instruments

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Accounting for Stock-Based Compensation

Earnings Per Share, Policy [Policy Text Block]

Income (Loss) Per Share

The following table sets forth the computation of basic and diluted income (loss) per common share (in thousands, except for per share amounts):



	Year Ended December 31,
	2013			2012			2011
Numerator:
Loss from continuing operations, net of income taxes	$	(53,606	)	$	(8,340	)	$	(424	)
Income from discontinued operations, net of income taxes	(16,048		)	73,047			8,296
Net income (loss)	$	(69,654	)	$	64,707		$	7,872
Denominator - Basic and Diluted:
Weighted average number of common shares outstanding	64,560			56,239			54,505
Earnings Per Common Share:
Loss from continuing operations, basic and diluted	$	(0.83	)	$	(0.15	)	$	(0.01	)
Income (loss) from discontinued operations, basic and diluted	(0.25		)	1.30			0.15
Income (loss) per common share, basic and diluted	$	(1.08	)	$	1.15		$	0.14

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

Schedule of Accounts, Notes, Loans and Financing Receivable



	December 31, 2013				December 31, 2012 ⁽¹⁾
	0 - 180 days	Over 180 days	Total		0 - 180 days	Over 180 days	Total
Government	37,344	9,490	46,834		41,124	2,744	43,868
Commercial	126,498	28,186	154,684		75,389	26,137	101,526
Patient	2,833	2,163	4,996		1,784	4,137	5,921
Gross accounts receivable	166,675	39,839	206,514		118,297	33,018	151,315
Allowance for doubtful accounts			(19,213	)			(22,212	)
Net accounts receivable			187,301				129,103


(1)	The December 31, 2012 balances include the remaining Pharmacy Services gross accounts receivables not sold as part of the 2012 Asset Purchase Agreement of $12.8 million over 180 days and the allowance for doubtful accounts includes $8.0 million related to these receivables. At December 31, 2013, none of the accounts receivable retained by the Company remained.

ProForma Schedule of Accounts Receivable Allowances [Table Text Block]

The following table shows the pro forma effect on the accounts receivable aging (in thousands):



	December 31, 2013							December 31, 2012
	0 - 180 days		Over 180 days		Total			0 - 180 days		Over 180 days			Total
Gross accounts receivable	$	166,675	$	39,839	$	206,514		$	118,297	$	33,018		$	151,315
Add: acquisition-related allowance	—		5,243		5,243			—		—			—
Less: Pharmacy Services accounts receivable	—		—		—			—		(12,840		)	(12,840		)
Pro forma gross accounts receivable	$	166,675	$	45,082	211,757			$	118,297	$	20,178		138,475
Allowance for doubtful accounts					(19,213		)						(22,212		)
Add: Acquisition-related allowance					(5,243		)						—
Less: Pharmacy Services allowance					—								8,045
Pro forma allowance for doubtful accounts					(24,456		)						(14,167		)
Pro forma net accounts receivable					$	187,301							$	124,308

The pro forma allowance for doubtful accounts as a percent of pro forma accounts receivable was 11.5% and 10.2% at December 31, 2013 and 2012, respectively.

Property, Plant and Equipment

Property and equipment is stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of assets as follows:



Asset	Useful Life
Computer hardware and software	3	-	5	years
Office equipment	3	-	5	years
Vehicles	4	-	5	years
Medical equipment	2	-	5	years
Furniture and fixtures			5	years

Property and equipment consists of the following (in thousands):



	December 31,
	2013			2012
Computer and office equipment, including equipment acquired under capital leases	$	20,440		$	14,443
Software capitalized for internal use	13,842			9,939
Vehicles, including equipment acquired under capital leases	2,056			1,540
Medical equipment	22,391			16,466
Work in progress	8,820			4,315
Furniture and fixtures	4,461			3,219
Leasehold improvements	12,232			7,164
Property and equipment, gross	84,242			57,086
Less: Accumulated depreciation	(42,630		)	(33,365		)
Property and equipment, net	$	41,612		$	23,721

ACQUISITIONS ACQUISITIONS (Tables)

12 Months Ended

Dec. 31, 2013

Business Acquisition [Line Items]

Business Acquisition, Integration, Restructuring and Other Related Costs [Text Block]

Acquisition and Integration Costs



	Year Ended December 31,
	2013		2012
Legal and professional fees	$	5,113	$	2,941
Financial advisory fees	4,713		—
Employee costs including redundant salaries and benefits and severance	3,554		806
Facilities consolidation and discontinuation	1,621		110
Other	1,129		189
Total	$	16,130	$	4,046

There were no acquisition and integration expenses in the year ended December 31, 2011.

CarePoint Partners Holding LLC

Business Acquisition [Line Items]

Schedule of Business Acquisitions, by Acquisition



	Estimated Fair Value (in thousands)
Cash	$	14
Accounts receivable	16,644
Inventories	3,263
Other current assets	272
Property and equipment	3,266
Identifiable intangible assets⁽¹⁾	16,700
Current liabilities	(8,128		)
Non-current liabilities	(621		)
Total identifiable net assets	31,410
Goodwill	187,228
Total cash and fair value of contingent consideration	$	218,638


(1)	The following table summarizes the provisional amounts and useful lives assigned to identifiable intangible assets:



	Weighted- Average Useful Lives	Amounts Recognized as of the Closing Date (in thousands)
Customer relationships	2 - 4 years	$	13,600
Trademarks	2 years	2,600
Non-compete agreements	5 years	500
Total identifiable intangible assets acquired		$	16,700

HomeChoice Partners, Inc.

Business Acquisition [Line Items]

Schedule of Business Acquisitions, by Acquisition



	Fair Value (in thousands)
Accounts receivable	$	9,693
Inventories	1,984
Other current assets	154
Property and equipment	2,432
Identifiable intangible assets⁽¹⁾	4,000
Other non-current assets	30
Current liabilities	(4,073		)
Total identifiable net assets	14,220
Goodwill	66,701
Total cash and fair value of contingent consideration	$	80,921


(1)	The following table summarizes the provisional amounts and useful lives assigned to identifiable intangible assets:



	Weighted- Average Useful Lives	Amounts Recognized as of Acquisition Date (in thousands)
Customer relationships	5 mo. - 3 years	$	2,000
Trademarks	23 months	1,000
Non-compete agreements	1 year	1,000
Total identifiable intangible assets acquired		$	4,000

InfuScience, Inc.

Business Acquisition [Line Items]

Schedule of Business Acquisitions, by Acquisition

InfuScience, Inc.

The table below summarizes the Company's assessment of the fair values of the assets acquired and liabilities assumed as of the acquisition date of InfuScience.



	Fair Value (in thousands)
Cash	$	23
Accounts receivable	4,938
Inventories	586
Other current assets	371
Property and equipment	751
Identifiable intangible assets⁽¹⁾	400
Other non-current assets	349
Current liabilities	(4,428		)
Total identifiable net assets	2,990
Goodwill	38,429
Total cash and fair value of contingent consideration	$	41,419


(1)	The following table summarizes the provisional amounts and useful lives assigned to identifiable intangible assets:



	Weighted- Average Useful Lives (Months)	Amounts Recognized as of Acquisition Date (in thousands)
Customer relationships	5 months	$	400
Total identifiable intangible assets acquired		$	400

All Current Acquirees

Business Acquisition [Line Items]

Business Acquisition, Pro Forma Information

Pro Forma Impact of Acquisitions



	Year Ended December 31,
	2013			2012			2011
Revenues	$	949,679		$	893,814		$	589,333
Net loss from continuing operations	$	(55,444	)	$	(23,352	)	$	(2,582	)
Basic loss per common share from continuing operations	$	(0.86	)	$	(0.42	)	$	(0.05	)
Diluted loss per common share from continuing operations	$	(0.86	)	$	(0.42	)	$	(0.05	)



	Year Ended December 31,
	2013		2012		2011
Interest expense	$	3,734	$	8,613	$	1,169
Amortization expense	$	576	$	4,094	$	400
Income tax expense (benefit)	$	2,785	$	4,357	$	(1,159	)

DISCONTINUED OPERATIONS DISCONTINUED OPERATIONS (Tables)

12 Months Ended

Dec. 31, 2013

DISCONTINUED OPERATIONS [Abstract]

Schedule of Disposal Groups, Including Discontinued Operations, Balance Sheet at Date of Disposal

On May 4, 2012, the carrying value of the assets included in the Pharmacy Services Asset Sale was as follows (in thousands):



	Carrying Value
Inventory	$	30,560
Prepaid expenses and other current assets	299
Total current assets	30,859
Property and equipment, net	1,592
Goodwill	11,754
Intangible assets, net	2,503
Total assets	$	46,708

Expenses Associated With Disposal Activities

The accrual activity consisted of the following (in thousands):



	Legal Settlement		Impairment Costs			Employee Severance and Other Benefits			Facility-Related Costs			Other Costs			Total
Balance at December 31, 2011	$	—	$	—		$	—		$	—		$	—		$	—
Expenses	—		5,839			5,279			1,071			1,198			13,387
Cash payments	—		—			(5,234		)	(82		)	(3,133		)	(8,449		)
Non-cash charges	—		(5,839		)	—			(989		)	2,024			(4,804		)
Balance at December 31, 2012	—		—			45			—			89			134
Expenses	15,000		—			186			—			7,410			22,596
Cash payments	—		—			(103		)	—			(6,261		)	(6,364		)
Non-cash charges	—		—			(36		)	—			(43		)	(79		)
Balance at December 31, 2013	$	15,000	$	—		$	92		$	—		$	1,195		$	16,287

Schedule of Disposal Groups, Including Discontinued Operations, Income Statement



	Years ended December 31,
	2013			2012		2011
Revenue	$	(75	)	$	466,747	$	1,263,520
Gross profit	(519		)	29,844		96,888
Operating expenses	7,118			38,612		77,727
Legal settlement expense	15,000			—		—
Bad debt expense	—			12,931		7,213
Interest (income) expense	(41		)	761		2,764
Gain on sale	6,548			101,624		—
Income tax expense	—			6,117		888
Income (loss) from discontinued operations, net of income taxes	$	(16,048	)	$	73,047	$	8,296

GOODWILL AND INTANGIBLE ASSETS GOODWILL AND INTANGIBLE ASSETS (Tables)

12 Months Ended

Dec. 31, 2013

GOODWILL AND INTANGIBLE ASSETS [Abstract]

Schedule of Goodwill

he changes in the carrying amount of goodwill by operating and reportable segment for the years ended December 31, 2013 and 2012, are as follows (in thousands):



	Infusion Services		Home Health Services		PBM Services		Total
Balance at December 31, 2011	$	265,859	$	33,784	$	12,744	$	312,387
Acquisitions	38,423		—		—		38,423
Balance at December 31, 2012	$	304,282	$	33,784	$	12,744	$	350,810
Acquisitions	254,304		—		—		254,304
Other adjustments	7		—		—		7
Balance at December 31, 2013	$	558,593	$	33,784	$	12,744	$	605,121

Schedule of Indefinite and Finite Lived Intangible Assets

Intangible assets consisted of the following as of December 31, 2013 and 2012 (in thousands):



	December 31, 2013							December 31, 2012
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Indefinite Lived Assets
Home Health certificates of need	$	9,600	$	—		$	9,600	$	9,600	$	—		$	9,600
Home Health nursing trademarks	5,800		—			5,800		5,800		—			5,800
	15,400		—			15,400		15,400		—			15,400
Finite Lived Assets
Infusion customer relationships	25,650		(12,062		)	13,588		9,300		(7,447		)	1,853
Infusion trademarks	6,200		(3,514		)	2,686		2,600		(2,407		)	193
Non-compete agreements	1,500		(950		)	550		—		—			—
	33,350		(16,526		)	16,824		11,900		(9,854		)	2,046
	$	48,750	$	(16,526	)	$	32,224	$	27,300	$	(9,854	)	$	17,446

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense

otal amortization expense of intangible assets was $6.7 million, $4.0 million, and $3.4 million for the years ended December 31, 2013, 2012, and 2011, respectively. Amortization expense is expected to be the following (in thousands):



Year ending December 31,	Estimated Amortization
2014	$	5,571
2015	4,966
2016	2,622
2017	2,385
2018	1,221
Thereafter	$	59
Total estimated amortization expense	$	16,824

RESTRUCTURING EXPENSE RESTRUCTURING AND OTHER EXPENSES (Tables)

12 Months Ended

Dec. 31, 2013

Phase One

Restructuring Cost and Reserve [Line Items]

Schedule of Restructuring Reserve by Type of Cost

The restructuring accrual activity consisted of the following (in thousands):



	Employee Severance and Other Benefits			Consulting Costs			Facility-Related Costs			Other Costs		Total
Balance as of December 31, 2011	$	2,109		$	50		$	1,289		$	—	$	3,448
Expenses	6			270			(61		)	—		215
Cash payments	(1,952		)	(300		)	(387		)	—		(2,639		)
Balance as of December 31, 2012	$	163		$	20		$	841		$	—	$	1,024
Expenses	(163		)	(20		)	118			—		(65		)
Cash payments	—			—			(438		)	—		(438		)
Balance as of December 31, 2013	$	—		$	—		$	521		$	—	$	521

Phase Two

Restructuring Cost and Reserve [Line Items]

Schedule of Restructuring Reserve by Type of Cost

The restructuring costs are included in restructuring and other expenses on the Consolidated Statements of Operations. As of December 31, 2013, there are restructuring accruals of $2.5 million related to Phase II included on the Consolidated Balance Sheets. The restructuring accrual activity consisted of the following (in thousands):



	Employee Severance and Other Benefits			Consulting Costs			Facility-Related Costs		Other Costs			Total
Balance as of December 31, 2011	$	—		$	—		$	—	$	—		$	—
Expenses	1,125			262			—		541			1,928
Cash payments	(566		)	(117		)	—		(541		)	(1,224		)
Balance as of December 31, 2012	$	559		$	145		$	—	$	—		$	704
Expenses	1,496			1,561			—		378			3,435
Cash payments	(1,159		)	(155		)	—		(344		)	(1,658		)
Balance as of December 31, 2013	$	896		$	1,551		$	—	$	34		$	2,481

PROPERTY AND EQUIPMENT PROPERTY AND EQUIPMENT (Tables)

12 Months Ended

Dec. 31, 2013

PROPERTY AND EQUIPMENT [Abstract]

Property, Plant and Equipment

Property and equipment is stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of assets as follows:



Asset	Useful Life
Computer hardware and software	3	-	5	years
Office equipment	3	-	5	years
Vehicles	4	-	5	years
Medical equipment	2	-	5	years
Furniture and fixtures			5	years

Property and equipment consists of the following (in thousands):



	December 31,
	2013			2012
Computer and office equipment, including equipment acquired under capital leases	$	20,440		$	14,443
Software capitalized for internal use	13,842			9,939
Vehicles, including equipment acquired under capital leases	2,056			1,540
Medical equipment	22,391			16,466
Work in progress	8,820			4,315
Furniture and fixtures	4,461			3,219
Leasehold improvements	12,232			7,164
Property and equipment, gross	84,242			57,086
Less: Accumulated depreciation	(42,630		)	(33,365		)
Property and equipment, net	$	41,612		$	23,721

DEBT DEBT (Tables)

12 Months Ended

Dec. 31, 2013

DEBT [Abstract]

Schedule of Debt

As of December 31, 2013 and 2012 the Company’s debt consisted of the following (in thousands):



	December 31,
	2013		2012
Revolving Credit Facility	$	40,003	$	—
Term Loan Facilities	395,000		—
Prior Credit Facility	—		—
2015 Notes	—		225,000
Capital leases	577		1,379
Total Debt	435,580		226,379
Less: Current portion	60,257		953
Long-term debt, net of current portion	$	375,323	$	225,426

Schedule of Extinguishment of Debt



	Amount
2015 Note redemption premium	$	12,162
Write-off of deferred financing costs	3,501
Legal fees and other expenses	235
Loss on extinguishment of debt	$	15,898

Schedule of Maturities of Long-term Debt

The estimated future maturities of the Company's debt as of December 31, 2013, including interest, is as follows (in thousands):



Year Ending December 31,	Amount
2014	$	45,188
2015	43,888
2016	42,588
2017	41,288
2018	39,988
Thereafter	323,979
Total future maturities	$	536,919

Schedule of Interest Expense by Debt Type

Interest Expense, net

Interest expense consisted of the following for each of the three years ended December 31, 2013 (in thousands):



	Year ended December 31,
	2013			2012			2011
Revolving Credit Facility	$	873		$	—		$	—
Term Loan Facilities	10,313			—			—
Prior Credit Facility	765			2,675			4,371
2015 Notes	13,960			23,063			23,063
Amortization of deferred financing costs	2,259			1,261			1,055
Expense allocated to discontinued operations	41			(761		)	(2,764		)
Other, net	(15		)	(171		)	(183		)
Interest expense, net	$	28,197		$	26,067		$	25,542

COMMITMENTS AND CONTINGENCIES Leases (Tables)

12 Months Ended

Dec. 31, 2013

COMMITMENTS AND CONTINGENCIES [Abstract]

Contractual Obligation, Fiscal Year Maturity Schedule

As of December 31, 2013, future minimum lease payments under operating and capital leases were as follows (in thousands):



	Operating Leases		Capital Leases		Total
2014	$	9,622	$	333	$	9,955
2015	7,771		438		8,209
2016	6,202		201		6,403
2017	5,038		39		5,077
2018	3,242		1		3,243
2019 and thereafter	3,177		—		3,177
Total	$	35,052	$	1,012	$	36,064

OPERATING AND REPORTABLE SEGMENTS OPERATING AND REPORTABLE SEGMENTS (Tables)

12 Months Ended

Dec. 31, 2013

OPERATING AND REPORTABLE SEGMENTS [Abstract]

Schedule of Segment Reporting Information, by Segment



	Year Ended December 31,
	2013			2012			2011
Results of Operations:
Revenue:
Infusion Services - product revenue	$	675,684		$	471,506		$	365,526
Infusion Services - service revenue	21,643			10,080			8,756
Total Infusion Services revenue	697,327			481,586			374,282
Home Health Services - service revenue	72,276			69,190			69,635
PBM Services - service revenue	72,592			111,861			110,589
Total revenue	$	842,195		$	662,637		$	554,506

Adjusted EBITDA by Segment before corporate overhead:
Infusion Services	$	60,677		$	36,764		$	35,128
Home Health Services	2,884			5,401			5,954
PBM Services	17,110			25,659			30,122
Total Segment Adjusted EBITDA	80,671			67,824			71,204
Corporate overhead	(32,042		)	(26,755		)	(23,308		)
Interest expense, net	(28,197		)	(26,067		)	(25,542		)
Loss on extinguishment of debt	(15,898		)	—			—
Income tax benefit (expense)	(2,538		)	4,439			(435		)
Depreciation	(13,555		)	(8,513		)	(6,591		)
Amortization of intangibles	(6,671		)	(3,957		)	(3,376		)
Stock-based compensation expense	(9,450		)	(6,122		)	(4,467		)
Acquisition and integration expenses	(16,130		)	(4,046		)	—
Restructuring and other expenses and investments	(9,796		)	(5,143		)	(7,909		)
Loss from continuing operations, net of income taxes	$	(53,606	)	$	(8,340	)	$	(424	)



	Year Ended December 31,
	2013		2012		2011
Supplemental Operating Data:
Capital Expenditures:
Infusion Services	$	15,972	$	6,685	$	4,826
Home Health Services	69		171		170
PBM Services	—		—		—
Corporate unallocated	9,576		4,130		2,857
Total Capital Expenditures	$	25,617	$	10,986	$	7,853

Depreciation Expense:
Infusion Services	$	8,640	$	4,347	$	5,242
Home Health Services	75		111		48
PBM Services	—		—		—
Corporate unallocated	4,840		4,055		1,301
Total Depreciation Expense	$	13,555	$	8,513	$	6,591

Total Assets:
Infusion Services	$	794,006	$	438,623	$	353,999
Home Health Services	64,428		62,403		64,672
PBM Services	25,239		36,354		40,418
Corporate unallocated	53,169		95,813		24,348
Assets from discontinued operations	—		—		59,005
Assets associated with discontinued operations, not sold	16		9,183		134,660
Total Assets	$	936,858	$	642,376	$	677,102

Goodwill:
Infusion Services	$	558,593	$	304,282	$	265,859
Home Health Services	33,784		33,784		33,784
PBM Services	12,744		12,744		12,744
Total Goodwill	$	605,121	$	350,810	$	312,387

INCOME TAXES INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2013

INCOME TAXES [Abstract]

Schedule of Components of Income Tax Expense (Benefit)

The Company’s federal and state income tax expense (benefit) is summarized in the following table (in thousands):



	Year Ended December 31,
	2013			2012			2011
Current
Federal	$	(866	)	$	(3,759	)	$	(167	)
State	(1,412		)	(676		)	(122		)
Total current	(2,278		)	(4,435		)	(289		)
Deferred
Federal	4,437			121			632
State	379			(125		)	92
Total deferred	4,816			(4		)	724
Total tax (benefit) provision	$	2,538		$	(4,439	)	$	435

Schedule of Deferred Tax Assets and Liabilities

The effect of temporary differences that give rise to a significant portion of deferred taxes is as follows (in thousands):



	December 31,
	2013			2012
Deferred tax assets:
Reserves not currently deductible	$	10,315		$	11,771
Net operating loss carryforwards	39,556			16,287
Goodwill and intangibles (tax deductible)	8,089			7,278
Accrued expenses	148			3,055
Stock based compensation	6,277			3,717
Other	417			1,778
Total deferred tax assets	64,802			43,886
Deferred tax liabilities:
Property basis differences	(506		)	(3,144		)
Indefinite-lived goodwill and intangibles	(16,122		)	(11,306		)
Less: valuation allowance	(63,281		)	(39,727		)
Net deferred tax liability	$	(15,107	)	$	(10,291	)

Schedule of Effective Income Tax Rate Reconciliation

The Company’s reconciliation of the statutory rate to the effective income tax rate is as follows (in thousands):



	Year Ended December 31,
	2013			2012			2011
Tax (benefit) provision at statutory rate	$	(17,874	)	$	(4,473	)	$	4
State tax (benefit) provision, net of federal taxes	(2,419		)	(587		)	36
Non-deductible transaction costs	317			—			—
Penalties	—			—			78
Change in tax contingencies	(1,157		)	(633		)	(675		)
Valuation allowance changes affecting income tax expense	23,493			1,104			778
Other	178			150			214
Tax (benefit) provision	$	2,538		$	(4,439	)	$	435

Schedule of Unrecognized Tax Benefits Roll Forward

A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):



	Year Ended December 31,
	2013			2012			2011
Unrecognized tax benefits balance at January 1,	$	2,754		$	2,605		$	2,869
Gross increases for tax positions of prior years	—			—			—
Gross increases for tax positions taken in current year	—			636			378
Settlements with taxing authorities	—			—			(212		)
Lapse of statute of limitations	(1,582		)	(487		)	(430		)
Unrecognized tax benefits balance at December 31,	$	1,172		$	2,754		$	2,605

STOCK-BASED COMPENSATION (Tables)

12 Months Ended

Dec. 31, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions

A binomial lattice-based valuation model is used to estimate the fair value of each option granted. Because of the limitations with closed-form valuation models, such as the Black-Scholes model, we have determined that this more flexible binomial model provides a better estimate of the fair value of our options. The fair value of each stock option award on the date of the grant was calculated using the following weighted-average assumptions:



	2013			2012			2011
Expected volatility	61.8		%	64.8		%	64.1		%
Risk-free interest rate	2.13		%	1.98		%	3.23		%
Expected life of options	5.5 years			5.8 years			5.2 years
Dividend rate	—			—			—
Fair value of options	$	6.24		$	4.00		$	2.53

Schedule of Share-based Compensation, Stock Options, Activity

Stock option activity for the Equity Compensation Plans through December 31, 2013 was as follows:



	Options		Weighted Average Exercise Price		Aggregate Intrinsic Value (thousands)		Weighted Average Remaining Contractual Life
Balance at December 31, 2012	4,885,215		$	5.97	$	23,463	7.8 years
Granted	1,928,500		$	11.25
Exercised	(517,979	)	$	4.83
Forfeited and expired	(562,915	)	$	8.57
Balance at December 31, 2013	5,732,821		$	7.59	$	6,185	7.7 years
Outstanding options less expected forfeitures at December 31, 2013	5,274,974		$	7.44	$	5,936	7.6 years
Exercisable at December 31, 2013	2,492,009		$	5.84	$	4,362	6.4 years

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range

The following table outlines our outstanding and exercisable stock options as of December 31, 2013:



	Options Outstanding				Options Exercisable
Range of Option Exercise Price	Outstanding Options	Weighted Average Exercise Price		Weighted Average Remaining Contractual Life	Options Exercisable	Weighted Average Exercise Price
$1.71 - $4.24	443,516	$	2.83	5.2 years	411,850	$	2.72
$4.42 - $6.61	1,104,875	$	5.03	6.5 years	768,053	$	5.13
$6.62- $6.65	1,856,582	$	6.63	7.8 years	879,922	$	6.63
$6.67 - $9.16	857,348	$	7.90	7.9 years	432,184	$	8.44
$11.04 - $16.63	1,470,500	$	12.01	9.2 years	—	$	—
All options	5,732,821	$	7.59	7.7 years	2,492,009	$	5.84

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity

Restricted stock award activity through December 31, 2013 was as follows:



	Restricted Stock		Weighted Average Award Date Fair Value		Weighted Average Remaining Recognition Period
Balance at December 31, 2012	70,000		$	7.52	0.4 years
Granted	370,000		$	12.31
Awards Vested	(70,000	)	$	7.52
Canceled	—		$	—
Balance at December 31, 2013	370,000		$	12.31	0.3 years

Schedule of Share-based Compensation, Stock Appreciation Rights Award Activity

SAR activity through December 31, 2013 was as follows:



	Stock Appreciation Right		Weighted Average Exercise Price		Weighted Average Remaining Recognition Period
Balance at December 31, 2012	380,000		$	6.72	1.8 years
Granted	—		$	—
Exercised	—		$	—
Canceled	(50,000	)	$	6.67
Balance at December 31, 2013	330,000		$	6.73	1.7 years

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) SELECTED QUARTERLY FINANCIAL DATA (Tables)

12 Months Ended

Dec. 31, 2013

SELECT QUARTERLY FINANCIAL DATA [Abstract]

Schedule of Quarterly Financial Information

A summary of unaudited quarterly financial information for the years ended December 31, 2013 and 2012 is as follows (in thousands except per share data):



	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
Year ended December 31, 2013
Revenue	$	199,071		$	190,733		$	208,879		$	243,512
Gross profit	$	63,237		$	65,012		$	68,682		$	74,883
Net loss from continuing operations	$	(7,470	)	$	(8,317	)	$	(22,442	)	$	(15,377	)
Net (loss) income from discontinued operations	$	(658	)	$	(563	)	$	(11,645	)	$	(3,182	)
Net (loss) income	$	(8,128	)	$	(8,880	)	$	(34,087	)	$	(18,559	)

Loss per share from continuing operations, basic and diluted	$	(0.13	)	$	(0.13	)	$	(0.35	)	$	(0.22	)
Loss per share from discontinued operations, basic and diluted	(0.01		)	(0.01		)	(0.18		)	(0.05		)
Loss income per share, basic and diluted	$	(0.14	)	$	(0.14	)	$	(0.53	)	$	(0.27	)

Year ended December 31, 2012
Revenue	$	155,633		$	155,901		$	170,365		$	180,738
Gross profit	$	53,522		$	53,041		$	58,004		$	60,393
Net (loss) income from continuing operations	$	(2,023	)	$	(4,293	)	$	(605	)	$	(1,419	)
Net income (loss) from discontinued operations	$	(680	)	$	76,059		$	(10,931	)	$	8,599
Net income (loss)	$	(2,703	)	$	71,766		$	(11,536	)	$	7,180

Loss per share from continuing operations, basic and diluted	$	(0.04	)	$	(0.07	)	$	(0.01	)	$	(0.03	)
Loss per share from discontinued operations, basic and diluted	(0.01		)	1.35			(0.19		)	0.15
Loss income per share, basic and diluted	$	(0.05	)	$	1.28		$	(0.20	)	$	0.12

NATURE OF BUSINESS NATURE OF BUSINESS (Details) $ in Millions	12 Months Ended
	Dec. 31, 2013 segment	Mar. 31, 2014 USD ($)	May 04, 2012 USD ($)
Segment Reporting Information [Line Items]
Number of Reportable Segments \| segment	3
Disposal Group, Including Discontinued Operation, Proceeds \| $			$ 173.8
Number of Operating Segments \| segment	3
Scenario, Forecast \| Home Health Services
Segment Reporting Information [Line Items]
Disposal Group, Including Discontinued Operation, Proceeds \| $		$ 60.0

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Cash and Cash Equivalents (Details)	12 Months Ended
	Dec. 31, 2013
Cash and Cash Equivalents [Line Items]
Cash Equivalents, Maturity Term Maximum	3 months

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts Receivable, Gross	$ 206,514	$ 151,315
Allowance for Doubtful Accounts	(19,213)	(22,212)
Accounts Receivable, Net, Current	187,301	129,103
Disposal Group, Including Discontinued Operations, Remaining Gross Receivables		(12,840)
Pro Forma Accounts Receivable	211,757	138,475
Disposal Group, Including Discontinued Operations, Remaining Allowance for Doubtful Accounts		8,045
Pro Forma Allowance for Doubtful Accounts Related to Continuing Operations	(24,456)	(14,167)
ProForma Net Trade Receivables	$ 187,301	$ 124,308
Percent Of Accounts Receivable	9.00%
Percent Of Pro Forma Accounts Receivable	11.50%	10.20%
0-180 Days
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts Receivable, Gross	$ 166,675	$ 118,297
Pro Forma Accounts Receivable	166,675	118,297
Over 180 Days
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts Receivable, Gross	39,839	33,018
Pro Forma Accounts Receivable	$ 45,082	$ 20,178
Percent Of Accounts Receivable	48.00%
Percent Of Pro Forma Accounts Receivable		70.20%
Government
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts Receivable, Gross	$ 46,834	$ 43,868
Government \| 0-180 Days
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts Receivable, Gross	37,344	41,124
Government \| Over 180 Days
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts Receivable, Gross	9,490	2,744
Commercial Customer
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts Receivable, Gross	154,684	101,526
Commercial Customer \| 0-180 Days
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts Receivable, Gross	126,498	75,389
Commercial Customer \| Over 180 Days
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts Receivable, Gross	28,186	26,137
Health Care Patient
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts Receivable, Gross	4,996	5,921
Health Care Patient \| 0-180 Days
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts Receivable, Gross	2,833	1,784
Health Care Patient \| Over 180 Days
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts Receivable, Gross	2,163	$ 4,137
All Current Acquirees
Accounts, Notes, Loans and Financing Receivable [Line Items]
Valuation Allowances and Reserves, Reserves of Businesses Acquired	$ (5,243)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2013
Computer hardware and software \| Minimum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Computer hardware and software \| Maximum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Office Equipment \| Minimum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Office Equipment \| Maximum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Vehicles \| Minimum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	4 years
Vehicles \| Maximum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Medical Equipment \| Minimum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	2 years
Medical Equipment \| Maximum
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Variable Interest Entity (Details) - USD ($) $ in Millions		8 Months Ended
	Apr. 19, 2013	Dec. 31, 2013
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Variable Interest Entity, Reporting Entity Involvement, Initial Investment, Amount		$ 6.9
Proceeds from Sale of Equity Method Investments	$ 8.6
Deposit Assets	$ 1.0
Sale of Affiliate Equity Investment, Period After Close Expected to Receive Additional Services or Cash		2 years
Due from Sale of Affiliate Equity Investment, Noncurrent		$ 2.2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Revenue Recognition (Details)	12 Months Ended
	Dec. 31, 2013
Revenue Recognition Policy [Abstract]
REVENUE RECOGNITION PERIOD	60 days

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Income (Loss) per Share, Basic and Diluted (Details) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2013 USD ($) $ / shares $ / warrant	Sep. 30, 2013 USD ($) $ / shares	Jun. 30, 2013 USD ($) $ / shares	Mar. 31, 2013 USD ($) $ / shares	Dec. 31, 2012 USD ($) $ / shares	Sep. 30, 2012 USD ($) $ / shares	Jun. 30, 2012 USD ($) $ / shares	Mar. 31, 2012 USD ($) $ / shares	Dec. 31, 2013 USD ($) $ / shares $ / warrant shares	Dec. 31, 2012 USD ($) $ / shares shares	Dec. 31, 2011 USD ($) $ / shares shares
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Income (Loss) from Continuing Operations Attributable to Parent \| $	$ (15,377)	$ (22,442)	$ (8,317)	$ (7,470)	$ (1,419)	$ (605)	$ (4,293)	$ (2,023)	$ (53,606)	$ (8,340)	$ (424)
Less: Income (loss) from discontinued operations, net of income taxes \| $									(16,048)	73,047	8,296
Net income \| $	$ (18,559)	$ (34,087)	$ (8,880)	$ (8,128)	$ 7,180	$ (11,536)	$ 71,766	$ (2,703)	$ (69,654)	$ 64,707	$ 7,872
Weighted Average Number of Shares Outstanding, Basic \| shares									64,560	56,239	54,505
Income (Loss) from Continuing Operations, Per Basic Share \| $ / shares	$ (0.22)	$ (0.35)	$ (0.13)	$ (0.13)	$ (0.03)	$ (0.01)	$ (0.07)	$ (0.04)	$ (0.83)	$ (0.15)	$ (0.01)
Income (Loss) from Discontinued Operations, Net of Tax, Per Basic Share \| $ / shares	(0.05)	(0.18)	(0.01)	(0.01)	0.15	(0.19)	1.35	(0.01)	(0.25)	1.30	0.15
Earnings Per Share, Basic \| $ / shares	$ (0.27)	$ (0.53)	$ (0.14)	$ (0.14)	$ 0.12	$ (0.20)	$ 1.28	$ (0.05)	$ (1.08)	$ 1.15	$ 0.14
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / warrant	10.00								10.00
Warrant
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount \| shares									3,100	3,400	3,400
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / warrant	10.00								10.00
Stock Compensation Plan [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount \| shares									6,100	5,000	4,600

STOCKHOLDERS' EQUITY (Details) $ / shares in Units, $ in Thousands			1 Months Ended	12 Months Ended
	Jun. 16, 2013 USD ($)	Apr. 24, 2013 USD ($) $ / shares shares	Mar. 31, 2010 shares	Dec. 31, 2013 USD ($) $ / warrant shares	Dec. 31, 2012 USD ($) shares	Dec. 31, 2011 USD ($) shares
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues		10,406,250
Share Price (in dollars per share) \| $ / shares		$ 12
Stock Issued During Period, Shares, Selling Stockholders		3,968,750
Stock Issued During Period, Value, New Issues \| $		$ 118,400
Repayments of Lines of Credit \| $		$ 21,000		$ 409,559	$ 1,307,872	$ 1,791,058
Proceeds from Issuance of Common Stock, Used To Fund Acquisition \| $	$ 61,100
Shares Paid for Tax Withholding for Share Based Compensation				0	25,999	25,273
Treasury Stock, Shares				2,582,520	2,582,520
Class of Warrant or Right, Issued			3,400,000
Class of Warrant or Right, Term				5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / warrant				10.00
Percentage Below Fair Value of Common Stock Issued to Trigger Increase in Common Stock Issued Upon Exercise of Warrants				90.00%
Class of Warrant or Right, Outstanding				3,100,000
Class of Warrant or Right, Fair Value of Warrants Outstanding \| $				$ 12,300
Expected volatility				62.00%
Class of Warrant or Right, Fair Value Assumptions, Risk Free Interest Rate				2.63%
Class of Warrant or Right, Fair Value Assumptions, Expected Dividend Rate				0.00%
Class of Warrant or Right, Fair Value Assumptions, Expected Term				5 years
Class of Warrant or Right, Fair Value Assumptions, Discount for Postvesting Restrictions				13.50%
Warrant
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / warrant				10.00
Stock Issued During Period, Shares, Conversion of Convertible Securities				78,567
Warrants exercised in cashless exercise				256,175

ACQUISITIONS CarePoint Business (Details)

4 Months Ended

Dec. 31, 2013

USD ($)

Aug. 23, 2013

USD ($)

location

patient

state

Dec. 31, 2012

USD ($)

Dec. 31, 2011

USD ($)

Business Acquisition [Line Items]

Goodwill

$ 605,121,000

$ 350,810,000

$ 312,387,000

CarePoint Partners Holding LLC

Business Acquisition [Line Items]

Number of customers | patient

20,500

Number of locations | location

Number of States in which Entity Operates | state

Business Combination, Consideration Transferred Excluding Contingent Consideration

$ 211,100,000

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

10,000,000

Business Combination, Provisional Information, Initial Accounting Incomplete, Trade Receivables

(2,200,000)

Business Combination Contingent Consideration, Initial Fair Value

9,800,000

14,000

16,644,000

3,263,000

272,000

Property and equipment

3,266,000

Identifiable intangible assets(1)

^[1]

16,700,000

Current liabilities

(8,128,000)

Non-current liabilities

(621,000)

Total identifiable net assets

31,410,000

Goodwill

187,228,000

Total cash and fair value of contingent consideration

218,638,000

Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual

55,800,000

Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual

$ 2,300,000

Term Loan B Facility | Secured Term Debt | CarePoint Partners Holding LLC

Business Acquisition [Line Items]

Debt Instrument, Face Amount

150,000,000

Customer Relationships | CarePoint Partners Holding LLC

Business Acquisition [Line Items]

Identifiable intangible assets(1)

13,600,000.000

Trademarks | CarePoint Partners Holding LLC

Business Acquisition [Line Items]

Identifiable intangible assets(1)

2,600,000.000

Noncompete Agreements | CarePoint Partners Holding LLC

Business Acquisition [Line Items]

Identifiable intangible assets(1)

$ 500,000.000

Minimum | Customer Relationships | CarePoint Partners Holding LLC

Business Acquisition [Line Items]

Weighted- Average Useful Lives

2 years

Maximum | Customer Relationships | CarePoint Partners Holding LLC

Business Acquisition [Line Items]

Weighted- Average Useful Lives

4 years

Maximum | Trademarks | CarePoint Partners Holding LLC

Business Acquisition [Line Items]

Weighted- Average Useful Lives

2 years

Maximum | Noncompete Agreements | CarePoint Partners Holding LLC

Business Acquisition [Line Items]

Weighted- Average Useful Lives

5 years

[1]

The following table summarizes the provisional amounts and useful lives assigned to identifiable intangible assets: Weighted- Average Useful Lives AmountsRecognized as of the Closing Date(in thousands)Customer relationships2 - 4 years $13,600Trademarks2 years 2,600Non-compete agreements5 years 500Total identifiable intangible assets acquired $16,700

ACQUISITIONS HomeChoice Partners, Inc. (Details)
patient in Thousands, $ in Thousands

3 Months Ended

11 Months Ended

12 Months Ended

Mar. 31, 2012

USD ($)

Dec. 31, 2013

USD ($)

Dec. 31, 2012

USD ($)

Feb. 01, 2013

USD ($)

location

patient

Dec. 31, 2011

USD ($)

Business Acquisition [Line Items]

Business combination, contingent consideration period

24 months

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

$ 2,900

Goodwill

$ 605,121

$ 350,810

$ 312,387

HomeChoice Partners, Inc.

Business Acquisition [Line Items]

Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual

$ 67,700

Business Acquisition, Percentage of Voting Interests Acquired

100.00%

Number of customers | patient

Number of locations | location

Business Acquisition, Cost of Acquired Entity, Initial Purchase Price

$ 72,900

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

20,000

Business combination, contingent consideration period

2 years

Business Combination Contingent Consideration, Initial Fair Value

8,000

Business Combination, contingent consideration, range of outcomes, value, high, first year

$ 10,000

Business Combination, contingent consideration, range of outcomes, value, high, second year

10,000

Business Combination, Contingent Consideration, Liability

2,200

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

5,800

Accounts receivable

9,693

Inventories

1,984

Other current assets

154

Property and equipment

2,432

Identifiable intangible assets(1)

^[1]

4,000

Other non-current assets

Current liabilities

(4,073)

Total identifiable net assets

14,220

Goodwill

66,701

Total cash and fair value of contingent consideration

80,921

Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual

$ 2,600

Customer Relationships | HomeChoice Partners, Inc.

Business Acquisition [Line Items]

Identifiable intangible assets(1)

2,000

Trademarks | HomeChoice Partners, Inc.

Business Acquisition [Line Items]

Identifiable intangible assets(1)

1,000

Noncompete Agreements | HomeChoice Partners, Inc.

Business Acquisition [Line Items]

Identifiable intangible assets(1)

$ 1,000

Minimum | Customer Relationships | HomeChoice Partners, Inc.

Business Acquisition [Line Items]

Weighted- Average Useful Lives (Months)

5 months

Maximum | Customer Relationships | HomeChoice Partners, Inc.

Business Acquisition [Line Items]

Weighted- Average Useful Lives (Months)

3 years

Maximum | Trademarks | HomeChoice Partners, Inc.

Business Acquisition [Line Items]

Weighted- Average Useful Lives (Months)

23 months

Maximum | Noncompete Agreements | HomeChoice Partners, Inc.

Business Acquisition [Line Items]

Weighted- Average Useful Lives (Months)

1 year

[1]

The following table summarizes the provisional amounts and useful lives assigned to identifiable intangible assets: Weighted- Average Useful Lives AmountsRecognized as ofAcquisition Date(in thousands)Customer relationships5 mo. - 3 years $2,000Trademarks23 months 1,000Non-compete agreements1 year 1,000Total identifiable intangible assets acquired $4,000

ACQUISITIONS InfuScience, Inc. (Details)
$ in Thousands

3 Months Ended

12 Months Ended

17 Months Ended

Mar. 31, 2012

USD ($)

Dec. 31, 2013

USD ($)

Dec. 31, 2012

USD ($)

Dec. 31, 2011

USD ($)

Dec. 31, 2013

USD ($)

Jul. 31, 2012

USD ($)

location

Business Acquisition [Line Items]

Business combination, contingent consideration period

24 months

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

$ 2,900

Business Combination, Acquisition Related Costs

$ 16,130

$ 4,046

$ 0

Goodwill

605,121

350,810

$ 312,387

$ 605,121

InfuScience, Inc.

Business Acquisition [Line Items]

Business Acquisition, Percentage of Voting Interests Acquired

100.00%

Business Acquisition, Cost of Acquired Entity, Initial Purchase Price

$ 38,300

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

$ 3,000

Number of locations | location

Business Combination Contingent Consideration, Initial Fair Value

$ 2,900

Payments for Previous Acquisition

1,700

Business Combination, Contingent Consideration, Liability

1,300

$ 1,300

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

$ 100

4,938

586

371

Property and equipment

751

Identifiable intangible assets(1)

^[1]

400

Other non-current assets

349

Current liabilities

(4,428)

Total identifiable net assets

2,990

Goodwill

38,429

Total cash and fair value of contingent consideration

41,419

Weighted- Average Useful Lives

5 months

Business Acquisition, Goodwill, Expected Tax Deductible Amount

7,700

Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual

$ 46,700

16,500

Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual

$ 4,400

$ (1,700)

Customer Relationships | InfuScience, Inc.

Business Acquisition [Line Items]

Identifiable intangible assets(1)

$ 400

[1]	Weighted- Average Useful Lives (Months) AmountsRecognized as ofAcquisition Date(in thousands)Customer relationships5 months $400Total identifiable intangible assets acquired $400

ACQUISITIONS Acquisition and Integration Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Business Combination, Separately Recognized Transactions [Line Items]
Business Combination, Acquisition Related Costs	$ 16,130	$ 4,046	$ 0
Other Acquisition and Integration Expenses [Member] \| All Current Acquirees
Business Combination, Separately Recognized Transactions [Line Items]
Legal Fees	5,113	2,941
Fees and Commissions	4,713	0
Business combination, employee related costs related to integration	3,554	806
Business combination, facilities costs related to integration activities	1,621	110
Business Combination, Integration Related Costs	1,129	189
Business Combination, Acquisition Related Costs	$ 16,130	$ 4,046

ACQUISITIONS Pro Forma Impact of Acquisitions (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Business Acquisition [Line Items]
Interest Income (Expense), Net	$ 28,197	$ 26,067	$ 25,542
Amortization of Intangible Assets	6,671	3,957	3,376
Income Tax Expense (Benefit)	2,538	(4,439)	435
All Current Acquirees
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Revenue	949,679	893,814	589,333
Business Acquisition, Pro Forma Net Income (Loss)	$ (55,444)	$ (23,352)	$ (2,582)
Business Acquisition, Pro Forma Earnings Per Share, Basic	$ (0.86)	$ (0.42)	$ (0.05)
Business Acquisition, Pro Forma Earnings Per Share, Diluted	$ (0.86)	$ (0.42)	$ (0.05)
Interest Income (Expense), Net	$ 3,734	$ 8,613	$ 1,169
Amortization of Intangible Assets	576	4,094	400
Income Tax Expense (Benefit)	$ 2,785	$ 4,357	$ (1,159)

DISCONTINUED OPERATIONS DISCONTINUED OPERATIONS (Details) $ in Thousands		3 Months Ended								8 Months Ended	12 Months Ended
	May 04, 2012 USD ($) location pharmacy	Dec. 31, 2013 USD ($)	Sep. 30, 2013 USD ($)	Jun. 30, 2013 USD ($)	Mar. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Sep. 30, 2012 USD ($)	Jun. 30, 2012 USD ($)	Mar. 31, 2012 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Proceeds	$ 173,800
Initial portion of the sale price received in cash at closing in the Pharmacy Services Asset Sale.	158,800
Disposal Group, Including Discontinued Operation, Proceeds Subsequent to Close for Retention of Certain Business	15,000
Disposal Group, Including Discontinued Operations, Contingent Sale Price		$ (6,400)									$ (6,400)
Disposal Groups, Including Discontinued Operations, Remaining Net Assets		0				$ 4,800				$ 4,800	0	$ 4,800
Disposal Group, Including Discontinued Operation, Inventory	30,560
Disposal group, including discontinued operations, prepaid expenses and other current assets	299
Assets of Disposal Group, Including Discontinued Operation, Current	30,859
Disposal Group, Including Discontinued Operation, Property, Plant, and Equipment, Net	1,592
Disposal Group, Including Discontinued Operation, Goodwill	11,754
Disposal Group, Including Discontinued Operation, Intangible Assets, Net	2,503
Assets of Disposal Group, Including Discontinued Operation	$ 46,708
Proceeds from Collaborators									$ 3,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability									2,900
Discontinued Operations, Gain On Disposal Before Costs Resulting From Disposal										108,200
Discontinued Operations Gain On Disposal Net of Costs Resulting From Disposal										101,600
Discontinued Operation, Transaction Costs From Disposal of Discontinued Operation										5,600
Discontinued Operations, Costs Included In Net Gain From Disposal of Discontinued Operation												13,387
Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax										79,200
Discontinued Operations, Deferred Tax Assets Included In Effective Tax Calculation										24,100
Discontinued Operations, Costs Included In Net Gain From Disposal of Discontinued Operation, Excluding Legal Settlement											7,600
Liabilities of Disposal Group, Including Discontinued Operation		16,300									16,300
Liabilities of Disposal Group, Including Discontinued Operation, Current		4,300									4,300
Liabilities of Disposal Group, Including Discontinued Operation, Noncurrent		12,000									12,000
Provision for Doubtful Accounts											20,963	14,035	$ 11,441
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest		(3,182)	$ (11,645)	$ (563)	$ (658)	8,599	$ (10,931)	$ 76,059	$ (680)
Community Pharmacy
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of locations \| pharmacy	27
Pharmacy Services Assets Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued Operations, Gain On Disposal Before Costs Resulting From Disposal											6,548	101,624	0
Discontinued Operations, Costs Included In Net Gain From Disposal of Discontinued Operation											22,596	13,387
Discontinued Operation, Tax Effect of Discontinued Operation										6,100	0	6,117	888
one time costs related to pharmacy services asset sale reserve, settled in cash											(6,364)	(8,449)
one time costs related to pharmacy services asset sale reserve, noncash											(79)	(4,804)
Disposal Group, Including Discontinued Operations, Accrued Liability Included In Calculation of Gain on Disposal		16,287				134				134	16,287	134
Disposal Group, Including Discontinued Operation, Revenue											(75)	466,747	1,263,520
Disposal Group, Including Discontinued Operation, Gross Profit (Loss)											(519)	29,844	96,888
Disposal Group, Including Discontinued Operation, Operating Expense											7,118	38,612	77,727
Disposal Group, Including Discontinued Operation, General and Administrative Expense											15,000	0	0
Provision for Doubtful Accounts											0	12,931	7,213
Disposal Group, Including Discontinued Operation, Interest Expense											(41)	761	2,764
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest											(16,048)	73,047	$ 8,296
mail order
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
locations not transferred as part of sale \| location	2
Asset Impairment \| Pharmacy Services Assets Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued Operations, Costs Included In Net Gain From Disposal of Discontinued Operation											0	5,839
one time costs related to pharmacy services asset sale reserve, settled in cash											0	0
one time costs related to pharmacy services asset sale reserve, noncash											0	(5,839)
Disposal Group, Including Discontinued Operations, Accrued Liability Included In Calculation of Gain on Disposal		0				0				0	0	0
Employee Severance \| Pharmacy Services Assets Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued Operations, Costs Included In Net Gain From Disposal of Discontinued Operation											186	5,279
one time costs related to pharmacy services asset sale reserve, settled in cash											(103)	(5,234)
one time costs related to pharmacy services asset sale reserve, noncash											(36)	0
Disposal Group, Including Discontinued Operations, Accrued Liability Included In Calculation of Gain on Disposal		92				45				45	92	45
Facility Closing \| Pharmacy Services Assets Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued Operations, Costs Included In Net Gain From Disposal of Discontinued Operation											0	1,071
one time costs related to pharmacy services asset sale reserve, settled in cash											0	(82)
one time costs related to pharmacy services asset sale reserve, noncash											0	(989)
Disposal Group, Including Discontinued Operations, Accrued Liability Included In Calculation of Gain on Disposal		0				0				0	0	0
Other Restructuring Costs \| Pharmacy Services Assets Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued Operations, Costs Included In Net Gain From Disposal of Discontinued Operation											7,410	1,198
one time costs related to pharmacy services asset sale reserve, settled in cash											(6,261)	(3,133)
one time costs related to pharmacy services asset sale reserve, noncash											(43)	2,024
Disposal Group, Including Discontinued Operations, Accrued Liability Included In Calculation of Gain on Disposal		1,195				89				89	1,195	89
All Current Acquirees \| Other Acquisition and Integration Expenses [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued Operations, Costs Included In Net Gain From Disposal of Discontinued Operation											15,000	0
Disposal Group, Including Discontinued Operations, Accrued Liability Included In Calculation of Gain on Disposal		$ 15,000				$ 0				$ 0	$ 15,000	$ 0

GOODWILL AND INTANGIBLE ASSETS Goodwill by operating and reportable segment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Schedule of Goodwill by Operating and Reportable Segment [Line Items]
Goodwill	$ 605,121	$ 350,810	$ 312,387
Goodwill, Acquired During Period	254,304	38,423
Goodwill, Other Changes	7
Infusion Services
Schedule of Goodwill by Operating and Reportable Segment [Line Items]
Goodwill	558,593	304,282	265,859
Goodwill, Acquired During Period	254,304	38,423
Goodwill, Other Changes	7
Home Health Services
Schedule of Goodwill by Operating and Reportable Segment [Line Items]
Goodwill	33,784	33,784	33,784
Goodwill, Acquired During Period	0
Goodwill, Other Changes	0
PBM Services
Schedule of Goodwill by Operating and Reportable Segment [Line Items]
Goodwill	12,744	$ 12,744	$ 12,744
Goodwill, Acquired During Period	0
Goodwill, Other Changes	$ 0

GOODWILL AND INTANGIBLE ASSETS Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Schedule of Indefinite and Finite Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 6,671	$ 3,957	$ 3,376
2014	5,571
2015	4,966
2016	2,622
2017	2,385
2018	1,221
Thereafter	59
indefinite lived intangible assets, gross	15,400	15,400
indefinite lived intangible assets accumulated amortization	0	0
Indefinite-Lived Intangible Assets (Excluding Goodwill)	15,400	15,400
Finite-Lived Intangible Assets, Gross	33,350	11,900
Finite-Lived Intangible Assets, Accumulated Amortization	(16,526)	(9,854)
Finite-Lived Intangible Assets, Net	16,824	2,046
intangible assets, gross	48,750	27,300
intangible assets, accumulated amortization	(16,526)	(9,854)
Intangible Assets, Net (Excluding Goodwill)	32,224	17,446
Certificates of Need
Schedule of Indefinite and Finite Lived Intangible Assets [Line Items]
indefinite lived intangible assets, gross	9,600	9,600
indefinite lived intangible assets accumulated amortization	0	0
Indefinite-Lived Intangible Assets (Excluding Goodwill)	9,600	9,600
Nursing Trademark
Schedule of Indefinite and Finite Lived Intangible Assets [Line Items]
indefinite lived intangible assets, gross	5,800	5,800
indefinite lived intangible assets accumulated amortization	0	0
Indefinite-Lived Intangible Assets (Excluding Goodwill)	5,800	5,800
Customer Relationships
Schedule of Indefinite and Finite Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	25,650	9,300
Finite-Lived Intangible Assets, Accumulated Amortization	(12,062)	(7,447)
Finite-Lived Intangible Assets, Net	13,588	1,853
Infusion Trademark
Schedule of Indefinite and Finite Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	6,200	2,600
Finite-Lived Intangible Assets, Accumulated Amortization	(3,514)	(2,407)
Finite-Lived Intangible Assets, Net	2,686	193
Noncompete Agreements
Schedule of Indefinite and Finite Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	1,500	0
Finite-Lived Intangible Assets, Accumulated Amortization	(950)	0
Finite-Lived Intangible Assets, Net	$ 550	$ 0
Minimum \| Customer Relationships
Schedule of Indefinite and Finite Lived Intangible Assets [Line Items]
Weighted- Average Useful Lives	5 months
Minimum \| Infusion Trademark
Schedule of Indefinite and Finite Lived Intangible Assets [Line Items]
Weighted- Average Useful Lives	23 months
Minimum \| Noncompete Agreements
Schedule of Indefinite and Finite Lived Intangible Assets [Line Items]
Weighted- Average Useful Lives	1 year
Maximum \| Customer Relationships
Schedule of Indefinite and Finite Lived Intangible Assets [Line Items]
Weighted- Average Useful Lives	4 years
Maximum \| Infusion Trademark
Schedule of Indefinite and Finite Lived Intangible Assets [Line Items]
Weighted- Average Useful Lives	3 years
Maximum \| Noncompete Agreements
Schedule of Indefinite and Finite Lived Intangible Assets [Line Items]
Weighted- Average Useful Lives	5 years

RESTRUCTURING EXPENSE Restructuring Phase I (Details) - USD ($) $ in Thousands	12 Months Ended			39 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Restructuring Reserve [Roll Forward]
Restructuring Charges	$ 7,771	$ 5,143	$ 7,909
Phase One
Restructuring Reserve [Roll Forward]
Restructuring Reserve	521	1,024	3,448	$ 521
Restructuring Charges	(65)	215	6,400	10,100
Restructuring Reserve, Settled with Cash	(438)	(2,639)
Restructuring Reserve	521	1,024	3,448	521
Phase One \| Employee Severance
Restructuring Reserve [Roll Forward]
Restructuring Reserve	0	163	2,109	0
Restructuring Charges	(163)	6	1,900	4,100
Restructuring Reserve, Settled with Cash	0	(1,952)
Restructuring Reserve	0	163	2,109	0
Phase One \| Consulting
Restructuring Reserve [Roll Forward]
Restructuring Reserve	0	20	50	0
Restructuring Charges	(20)	270	2,900	4,300
Restructuring Reserve, Settled with Cash	0	(300)
Restructuring Reserve	0	20	50	0
Phase One \| Facility Closing
Restructuring Reserve [Roll Forward]
Restructuring Reserve	521	841	1,289	521
Restructuring Charges	118	(61)	1,600	1,700
Restructuring Reserve, Settled with Cash	(438)	(387)
Restructuring Reserve	521	841	1,289	521
Phase One \| Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Restructuring Reserve	0	0	0	0
Restructuring Charges	0	0
Restructuring Reserve, Settled with Cash	0	0
Restructuring Reserve	$ 0	$ 0	$ 0	$ 0

RESTRUCTURING EXPENSE Restructuring Phase II (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Restructuring Reserve [Roll Forward]
Restructuring Charges	$ 7,771	$ 5,143	$ 7,909
Phase Two
Restructuring Reserve [Roll Forward]
Restructuring Reserve	2,481	704	0
Restructuring Charges	3,435	1,928
Restructuring Reserve, Settled with Cash	(1,658)	(1,224)
Restructuring Reserve	2,481	704	0
Phase Two \| Employee Severance
Restructuring Reserve [Roll Forward]
Restructuring Reserve	896	559	0
Restructuring Charges	1,500	1,125
Restructuring Reserve, Settled with Cash	(1,159)	(566)
Restructuring Reserve	896	559	0
Phase Two \| Consulting
Restructuring Reserve [Roll Forward]
Restructuring Reserve	1,551	145	0
Restructuring Charges	1,600	262
Restructuring Reserve, Settled with Cash	(155)	(117)
Restructuring Reserve	1,551	145	0
Phase Two \| Facility Closing
Restructuring Reserve [Roll Forward]
Restructuring Reserve	0	0	0
Restructuring Charges	0	0
Restructuring Reserve, Settled with Cash	0	0
Restructuring Reserve	0	0	0
Phase Two \| Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Restructuring Reserve	34	0	0
Restructuring Charges	400	541
Restructuring Reserve, Settled with Cash	(344)	(541)
Restructuring Reserve	34	$ 0	$ 0
Phase Two
Restructuring Reserve [Roll Forward]
Restructuring Reserve	2,481
Restructuring Reserve	$ 2,481

RESTRUCTURING EXPENSE Transitional expenses (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
RESTRUCTURING AND OTHER EXPENSES [Abstract]
Transitional Expenses	$ 4.4	$ 3.0	$ 1.5
Transitional Expense, State Tax Related		$ 0.8

PROPERTY AND EQUIPMENT PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property, Plant and Equipment [Line Items]
Computer and office equipment, including equipment acquired under capital leases	$ 20,440	$ 14,443
Software capitalized for internal use	13,842	9,939
Vehicles, including equipment acquired under capital leases	2,056	1,540
Medical equipment	22,391	16,466
Work in progress	8,820	4,315
Furniture and fixtures	4,461	3,219
Leasehold improvements	12,232	7,164
Property, Plant and Equipment, Gross	84,242	57,086
Less: Accumulated depreciation	(42,630)	(33,365)
Property and equipment, net	41,612	23,721
Depreciation	13,555	8,513	$ 6,591
Capitalized Computer Software, Amortization	1,724	1,325	$ 800
Impairment of Long-Lived Assets to be Disposed of		5,800
Software and Software Development Costs
Property, Plant and Equipment [Line Items]
Work in progress	$ 700	$ 1,300

DEBT (Details) - USD ($)			12 Months Ended
DEBT (Details) - USD ($)	Dec. 31, 2013	Jul. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Feb. 11, 2014	Aug. 19, 2013	Jun. 03, 2013	Apr. 19, 2013	Jul. 03, 2012	Mar. 25, 2010
Debt Instrument [Line Items]
Long-term Debt	$ 536,919,000		$ 536,919,000
long term debt and capital lease obligations, total	435,580,000		435,580,000	$ 226,379,000
Long-term Debt and Capital Lease Obligations, Current	60,257,000		60,257,000	953,000
Long-term Debt and Capital Lease Obligations	375,323,000		375,323,000	225,426,000
Deposit Assets									$ 1,000,000
Loss on extinguishment of debt			$ (15,898,000)	0	$ 0
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage			0.50%
Repayments of Long-term Debt			$ 5,000,000	0	0
Deferred Finance Costs, Net	21,900,000		21,900,000
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months	45,188,000		45,188,000
Long-term Debt, Maturities, Repayments of Principal in Year Two	43,888,000		43,888,000
Long-term Debt, Maturities, Repayments of Principal in Year Three	42,588,000		42,588,000
Long-term Debt, Maturities, Repayments of Principal in Year Four	41,288,000		41,288,000
Long-term Debt, Maturities, Repayments of Principal in Year Five	39,988,000		39,988,000
Long-term Debt, Maturities, Repayments of Principal after Year Five	$ 323,979,000		323,979,000
Amortization of deferred financing costs			2,259,000	1,261,000	1,055,000
Interest Expense, Other			(15,000)	(171,000)	(183,000)
Interest Income (Expense), Net			$ 28,197,000	$ 26,067,000	25,542,000
Line of Credit Facility, Interest Rate During Period			5.43%	4.69%
Prior Revolving Credit Facility
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity										$ 125,000,000
Debt Instrument, Basis Spread on Variable Rate			3.50%
Interest Expense, Debt			$ 765,000	$ 2,675,000	4,371,000
Senior Unsecured 10.25% Notes
Debt Instrument [Line Items]
Interest Expense, Debt			$ 13,960,000	23,063,000	23,063,000
Senior Secured Revolving Credit Facility
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Effective Percentage	5.46%		5.46%
Interest Expense, Debt			$ 873,000	0	0
Term Loan B Facility
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Effective Percentage	6.50%		6.50%
Line of Credit Facility, Periodic Payment, Principal, Percentage			1.25%
Payments of Debt Restructuring Costs	$ 500,000		$ 500,000.0
Interest rate base, minimum			1.25%
Interest Expense, Debt			$ 10,313,000	0	$ 0
Senior Credit Facilities
Debt Instrument [Line Items]
Debt Instrument, Debt Default, Interest Rate, Penalty Increase			2.00%
Line of Credit Facility, Borrowing Capacity, Percentage Threshold for Leverage Covenants			25.00%
Senior Credit Facilities \| Senior Secured Revolving Credit Facility
Debt Instrument [Line Items]
Long-term Debt	40,003,000		$ 40,003,000	0
Line of Credit Facility, Maximum Borrowing Capacity		$ 75,000,000
Senior Credit Facilities \| Term Loan B Facility
Debt Instrument [Line Items]
Long-term Debt	395,000,000		395,000,000	0
Debt Instrument, Face Amount		250,000,000
Senior Credit Facilities \| Delayed Draw Term Loan B Facility
Debt Instrument [Line Items]
Debt Instrument, Face Amount		150,000,000
Revolving Credit Facility \| Revolving Credit Facility
Debt Instrument [Line Items]
Long-term Debt	$ 0		$ 0	$ 0
Unsecured Debt \| Senior Unsecured 10.25% Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	10.25%		10.25%	10.25%	10.25%						10.25%
Long-term Debt	$ 0		$ 0	$ 225,000,000
Deposit Assets		$ 107,800,000
2015 Note redemption premium			12,162,000
Write-off of deferred financing costs			3,501,000
Legal fees and other expenses			235,000
Loss on extinguishment of debt			(15,898,000)
Debt Instrument, Face Amount								$ 225,000,000
Debt Instrument, Redemption Amount for Each Thousand Dollars of Principal							$ 1,051.25	1,056.25
Debt Instrument, Principal Base Amount Offered to be Redeemed								$ 1,000.00
Debt Instrument, Percentage of Aggregate Principal, Consents Received to Amend Note Provisions		56.10%
Repayments of Long-term Debt		$ 133,300,000
Repayments of Interest on Long Term Debt		$ 4,300,000
Capital Lease Obligations \| Capital Lease Obligations
Debt Instrument [Line Items]
Capital Lease Obligations	577,000		$ 577,000	$ 1,379,000
Eurodollar \| Senior Credit Facilities
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate			5.25%
Base Rate \| Senior Credit Facilities
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate			4.25%
Exjade Litigation
Debt Instrument [Line Items]
Loss Contingency Accrual	$ 15,000,000		$ 15,000,000
Subsequent Event \| Unsecured Debt \| Senior Unsecured 8.875% Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount						$ 200,000,000.0
Subsequent Event \| Eurodollar \| Term Loan B Facility
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate			5.25%
Subsequent Event \| Base Rate \| Term Loan B Facility
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate			4.25%

COMMITMENTS AND CONTINGENCIES Legal Proceedings (Details) - USD ($)		12 Months Ended
	Dec. 31, 2013	Dec. 31, 2013
Loss Contingencies [Line Items]
Interest rate, legal settlement		3.25%
Loss Contingency, Damages Sought, Value		$ 3,500,000.0
Exjade Litigation
Loss Contingencies [Line Items]
Loss Contingency, Loss in Period		15,000,000.0
Term Loan B Facility
Loss Contingencies [Line Items]
Payments of Debt Restructuring Costs	$ 500,000	$ 500,000.0

COMMITMENTS AND CONTINGENCIES Legal Settlements (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Loss Contingencies [Line Items]
Litigation Settlement, Expense	$ 0.8	$ 4.8
State and Local Jurisdiction
Loss Contingencies [Line Items]
Payments for Legal Settlements		0.6
Federal Government
Loss Contingencies [Line Items]
Payments for Legal Settlements		$ 4.4

COMMITMENTS AND CONTINGENCIES Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Operating Leases, Future Minimum Payments Due, Next Twelve Months	$ 9,622
Capital Leases, Future Minimum Payments Due, Next Twelve Months	333
future minimum payments due, current	9,955
Operating Leases, Future Minimum Payments, Due in Two Years	7,771
Capital Leases, Future Minimum Payments Due in Two Years	438
future minimum payments due in two years	8,209
Operating Leases, Future Minimum Payments, Due in Three Years	6,202
Capital Leases, Future Minimum Payments Due in Three Years	201
future minimum payments due in three years	6,403
Operating Leases, Future Minimum Payments, Due in Four Years	5,038
Capital Leases, Future Minimum Payments Due in Four Years	39
future minimum payments due in four years	5,077
Operating Leases, Future Minimum Payments, Due in Five Years	3,242
Capital Leases, Future Minimum Payments Due in Five Years	1
future minimum payments due in five years	3,243
Operating Leases, Future Minimum Payments, Due Thereafter	3,177
Capital Leases, Future Minimum Payments Due Thereafter	0
future minimum leases due thereafter	3,177
Operating Leases, Future Minimum Payments Due	35,052
Capital Leases, Future Minimum Payments Due	1,012
future minimum payments due	36,064
Operating Leases, Rent Expense	$ 7,900	$ 6,200	$ 6,300
Minimum
Future minimum lease payment for operating and capital leases [Line Items]
capital lease interest rate	3.00%
Maximum
Future minimum lease payment for operating and capital leases [Line Items]
capital lease interest rate	7.00%

COMMITMENTS AND CONTINGENCIES Purchase Commitments (Details) $ in Millions	12 Months Ended
	Dec. 31, 2013 USD ($)
COMMITMENTS AND CONTINGENCIES [Abstract]
Long-term Purchase Commitment, Amount	$ 37.3

OPERATING AND REPORTABLE SEGMENTS OPERATING AND REPORTABLE SEGMENTS (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Gross									$ 675,684	$ 471,506	$ 365,526
Sales Revenue, Services, Other									166,511	191,131	188,980
Revenues	$ 243,512	$ 208,879	$ 190,733	$ 199,071	$ 180,738	$ 170,365	$ 155,901	$ 155,633	842,195	662,637	554,506
Adjusted EBITDA									80,671	67,824	71,204
Interest expense, net									(28,197)	(26,067)	(25,542)
Loss on extinguishment of debt									(15,898)	0	0
Income tax benefit (expense)									(2,538)	4,439	(435)
Depreciation									(13,555)	(8,513)	(6,591)
Amortization of intangibles									(6,671)	(3,957)	(3,376)
Stock-based compensation expense									(9,450)	(6,122)	(4,467)
Acquisition and integration expenses									(16,130)	(4,046)	0
Restructuring and other expenses and investments									(9,796)	(5,143)	(7,909)
Income (Loss) from Continuing Operations Attributable to Parent	(15,377)	$ (22,442)	$ (8,317)	$ (7,470)	(1,419)	$ (605)	$ (4,293)	$ (2,023)	(53,606)	(8,340)	(424)
Expenditures for Additions to Long-Lived Assets									25,617	10,986	7,853
Assets	936,858				642,376				936,858	642,376	677,102
Goodwill	605,121				350,810				605,121	350,810	312,387
Infusion Services
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Gross									675,684	471,506	365,526
Sales Revenue, Services, Other									21,643	10,080	8,756
Revenues									697,327	481,586	374,282
Adjusted EBITDA									60,677	36,764	35,128
Depreciation									(8,640)	(4,347)	(5,242)
Expenditures for Additions to Long-Lived Assets									15,972	6,685	4,826
Assets	794,006				438,623				794,006	438,623	353,999
Goodwill	558,593				304,282				558,593	304,282	265,859
Home Health Services
Segment Reporting Information [Line Items]
Sales Revenue, Services, Other									72,276	69,190	69,635
Adjusted EBITDA									2,884	5,401	5,954
Depreciation									(75)	(111)	(48)
Expenditures for Additions to Long-Lived Assets									69	171	170
Assets	64,428				62,403				64,428	62,403	64,672
Goodwill	33,784				33,784				33,784	33,784	33,784
PBM Services
Segment Reporting Information [Line Items]
Sales Revenue, Services, Other									72,592	111,861	110,589
Adjusted EBITDA									17,110	25,659	30,122
Depreciation									0	0	0
Expenditures for Additions to Long-Lived Assets									0	0	0
Assets	25,239				36,354				25,239	36,354	40,418
Goodwill	12,744				12,744				12,744	12,744	12,744
Corporate
Segment Reporting Information [Line Items]
Adjusted EBITDA									(32,042)	(26,755)	(23,308)
Depreciation									(4,840)	(4,055)	(1,301)
Expenditures for Additions to Long-Lived Assets									9,576	4,130	2,857
Assets	53,169				95,813				53,169	95,813	24,348
Assets from discontinued operations
Segment Reporting Information [Line Items]
Assets	0				0				0	0	59,005
Assets associated with discontinued operations, not sold
Segment Reporting Information [Line Items]
Assets	$ 16				$ 9,183				$ 16	$ 9,183	$ 134,660

CONCENTRATION OF RISK CONCENTRATION OF RISK (Details)	12 Months Ended
CONCENTRATION OF RISK CONCENTRATION OF RISK (Details)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Customer Concentration Risk
Concentration Risk [Line Items]
Concentration of Risk, Percentage	21.00%	18.00%	13.00%
Product Concentration Risk
Concentration Risk [Line Items]
Concentration of Risk, Percentage	18.00%	19.00%	25.00%

INCOME TAXES INCOME TAXES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current
Federal	$ (866)	$ (3,759)	$ (167)
State	(1,412)	(676)	(122)
Total current	(2,278)	(4,435)	(289)
Deferred Tax Liabilities, Gross [Abstract]
Federal	4,437	121	632
State	379	(125)	92
Total deferred	4,816	(4)	724
Income Tax Expense (Benefit)	2,538	(4,439)	435
Reserves not currently deductible	10,315	11,771
Net operating loss carryforwards	39,556	16,287
Goodwill and intangibles (tax deductible)	8,089	7,278
Accrued expenses	148	3,055
Stock based compensation	6,277	3,717
Other	417	1,778
Deferred Tax Assets, Gross	64,802	43,886
Deferred Tax Liabilities, Property, Plant and Equipment	(506)	(3,144)
Deferred Tax Liabilities, Goodwill and Intangible Assets	(16,122)	(11,306)
Deferred Tax Assets, Valuation Allowance	(63,281)	(39,727)
Deferred Tax Liabilities, Net	(15,107)	(10,291)
Tax (benefit) provision at statutory rate	(17,874)	(4,473)	4
State tax (benefit) provision, net of federal taxes	(2,419)	(587)	36
Non-deductible transaction costs	317	0	0
Penalties	0	0	78
Change in tax contingencies	(1,157)	(633)	(675)
Valuation allowance changes affecting income tax expense	23,493	1,104	778
Other	178	$ 150	$ 214
Future Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net	17,900
Internal Revenue Service (IRS)
Deferred Tax Liabilities, Gross [Abstract]
Operating Loss Carryforwards	112,000
Operating Loss Carryforwards, Limitations on Use, Amount	23,900
State and Local Jurisdiction
Deferred Tax Liabilities, Gross [Abstract]
Operating Loss Carryforwards	$ 138,400

INCOME TAXES Unrecognized Tax Benefit (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	$ 200
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits balance at January 1,	2,754	$ 2,605	$ 2,869
Gross increases for tax positions of prior years	0	0	0
Gross increases for tax positions taken in current year	0	636	378
Settlements with taxing authorities	0	0	(212)
Lapse of statute of limitations	(1,582)	(487)	(430)
Unrecognized tax benefits balance at December 31,	1,172	2,754	$ 2,605
Unrecognized Tax Benefits, Interest on Income Taxes Accrued	$ 100	$ 300

STOCK-BASED COMPENSATION - Equity Plans and Stock Options (Narrative) (Details) - shares			12 Months Ended
	May 07, 2013	Jun. 10, 2010	Dec. 31, 2013	Mar. 25, 2010	Jan. 02, 2008	Jan. 01, 2008
Stock Appreciation Rights (SARs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			0
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			1,928,500
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			370,000
2008 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		6,855,000				3,580,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		3,275,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			971,658
CHS 2006 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation agreement by share-based payment awared, number of shares originally authorized				13,000,000
BioScrip/CHS Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation agreement by share-based payment awared, number of shares originally authorized				3,106,315
rollover options				716,086
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			2,390,229
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			800,361
Director \| 2008 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	800,000				500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	300,000

STOCK-BASED COMPENSATION - Stock Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Net proceeds from exercise of employee stock compensation plans	$ 2,549,000	$ 8,611,000	$ 3,198,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options	2,492,009	1,900,000	3,300,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	7 years 8 months 26 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 13,100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 3,800,000	$ 4,400,000	$ 2,500,000
Option Exercise Price, Range One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options	411,850
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	5 years 2 months 27 days
Option Exercise Price, Range Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options	768,053
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	6 years 6 months 10 days
Option Exercise Price, Range Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options	879,922
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	7 years 9 months 23 days
Option Exercise Price, Range Four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options	432,184
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	7 years 10 months 26 days
Option Exercise Price, Range Five
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options	0
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	9 years 2 months 22 days
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Allocated Share-based Compensation Expense	$ 6,000,000	$ 4,600,000	$ 3,700,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	61.80%	64.80%	64.10%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	2.13%	1.98%	3.23%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years 6 months	5 years 9 months 18 days	5 years 2 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 6.24	$ 4.00	$ 2.53
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 7.59	$ 5.97
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	$ 6,184,900	$ 23,462,800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	5,732,821	4,885,215
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 11.25
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,928,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	(517,979)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$ 4.83
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period	(562,915)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price	$ 8.57
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	7 years 8 months 12 days	7 years 9 months 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	5,274,974
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$ 7.44
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	$ 5,936,200
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	7 years 7 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	2,492,009
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price	$ 5.84
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value	$ 4,362,300
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term	6 years 5 months 6 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options	5,732,821
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price	$ 7.59
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price	$ 5.84
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years
Employee Stock Option \| Option Exercise Price, Range One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options	443,516
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price	$ 2.83
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price	$ 2.72
Employee Stock Option \| Option Exercise Price, Range Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options	1,104,875
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price	$ 5.03
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price	$ 5.13
Employee Stock Option \| Option Exercise Price, Range Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options	1,856,582
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price	$ 6.63
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price	$ 6.63
Employee Stock Option \| Option Exercise Price, Range Four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options	857,348
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price	$ 7.90
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price	$ 8.44
Employee Stock Option \| Option Exercise Price, Range Five
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options	1,470,500
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price	$ 12.01
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price	0.00
Minimum \| Option Exercise Price, Range One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	1.71
Minimum \| Option Exercise Price, Range Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	4.42
Minimum \| Option Exercise Price, Range Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	6.04
Minimum \| Option Exercise Price, Range Four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	6.65
Minimum \| Option Exercise Price, Range Five
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 7.95
Minimum \| Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent	100.00%
Maximum \| Option Exercise Price, Range One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 4.24
Maximum \| Option Exercise Price, Range Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	6.00
Maximum \| Option Exercise Price, Range Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	6.62
Maximum \| Option Exercise Price, Range Four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	7.73
Maximum \| Option Exercise Price, Range Five
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 9.56

STOCK-BASED COMPENSATION - Restricted Stock Award Activity (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Available shares reduced per restricted stock share issued	$ 1.53
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested	$ 0.5	$ 2.3	$ 0.5
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	4 months
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 0.5	$ 0.8	0.6
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance (in shares)	70,000
Granted (in shares)	370,000
Awards Vested (in shares)	(70,000)
Canceled (in shares)	0
Ending balance (in shares)	370,000	70,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Beginning balance (dollars per share)	$ 7.52
Granted (dollars per share)	12.31
Awards Vested (dollars per share)	7.52
Canceled (dollars per share)	0.00
Ending balance (dollars per share)	$ 12.31	$ 7.52
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Weighted average remaining recognition period, balance	4 months 1 day	4 months 24 days
Allocated Share-based Compensation Expense	$ 3.5	$ 0.4	0.5
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options	$ 1.2
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Allocated Share-based Compensation Expense	$ 6.0	$ 4.6	$ 3.7
2008 Plan \| Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	1 year
2008 Plan \| Minimum \| Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
2008 Plan \| Minimum \| Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	1 year
2008 Plan \| Director \| Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	1 year

STOCK-BASED COMPENSATION - Performance Units (Details)	12 Months Ended
STOCK-BASED COMPENSATION - Performance Units (Details)	Dec. 31, 2013 USD ($)
2008 Plan \| Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Annual Grant Limit, Value	$ 1,000,000.0

STOCK-BASED COMPENSATION - SAR Activity (Details) - Stock Appreciation Rights (SARs) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Holding Period	1 year
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Allocated Share-based Compensation Expense	$ 0.0	$ 1.1	$ 0.3
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance (in shares)	380,000
Granted (in shares)	0
Exercised (in shares)	0
Canceled (in shares)	(50,000)
Ending balance (in shares)	330,000	380,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Beginning balance (dollars per share)	$ 6.72
Granted (dollars per share)	0.00
Exercised (dollars per share)	0.00
Canceled (dollars per share)	6.67
Ending balance (dollars per share)	$ 6.73	$ 6.72
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Weighted average remaining recognition period, balance	1 year 8 months 1 day	1 year 9 months 18 days
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Share-based Awards Other than Options	$ 0.3
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 8 months 18 days
Payments of Stock Issuance Costs	$ 0.0	$ 0.3	$ 0.0

STOCK-BASED COMPENSATION Employee Stock Purchase Plan (Details) - shares	May 07, 2013	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Stock Ownership Plan, Shares to be Registered		750,000
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent	85.00%

DEFINED CONTRIBUTION PLAN DEFINED CONTRIBUTION PLANS (Details) $ in Millions	12 Months Ended
	Dec. 31, 2013 USD ($)
DEFINED CONTRIBUTION PLANS [Abstract]
Defined Contribution Plan, Maximum Annual Contribution Per Employee, Percent	100.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0.5

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) SELECTED QUARTERLY FINANCIAL DATA (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
SELECTED QUARTERLY FINANCIAL DATA [Abstract]
Health Care Organization, Revenue	$ 243,512	$ 208,879	$ 190,733	$ 199,071	$ 180,738	$ 170,365	$ 155,901	$ 155,633	$ 842,195	$ 662,637	$ 554,506
Gross Profit	74,883	68,682	65,012	63,237	60,393	58,004	53,041	53,522	271,814	224,960	215,415
Income (Loss) from Continuing Operations Attributable to Parent	(15,377)	(22,442)	(8,317)	(7,470)	(1,419)	(605)	(4,293)	(2,023)	(53,606)	(8,340)	(424)
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	(3,182)	(11,645)	(563)	(658)	8,599	(10,931)	76,059	(680)
Net Income (Loss) Attributable to Parent	$ (18,559)	$ (34,087)	$ (8,880)	$ (8,128)	$ 7,180	$ (11,536)	$ 71,766	$ (2,703)	$ (69,654)	$ 64,707	$ 7,872
Income (Loss) from Continuing Operations, Per Basic Share	$ (0.22)	$ (0.35)	$ (0.13)	$ (0.13)	$ (0.03)	$ (0.01)	$ (0.07)	$ (0.04)	$ (0.83)	$ (0.15)	$ (0.01)
Income (Loss) from Discontinued Operations, Net of Tax, Per Basic Share	(0.05)	(0.18)	(0.01)	(0.01)	0.15	(0.19)	1.35	(0.01)	(0.25)	1.30	0.15
Earnings Per Share, Basic	$ (0.27)	$ (0.53)	$ (0.14)	$ (0.14)	$ 0.12	$ (0.20)	$ 1.28	$ (0.05)	$ (1.08)	$ 1.15	$ 0.14

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

SUBSEQUENT EVENTS SUBSEQUENT EVENTS (Details) - USD ($)	1 Months Ended	12 Months Ended
SUBSEQUENT EVENTS SUBSEQUENT EVENTS (Details) - USD ($)	Feb. 28, 2014	Dec. 31, 2013	Feb. 11, 2014	Feb. 01, 2014	Jan. 31, 2014	Jul. 31, 2013	May 04, 2012
Subsequent Event [Line Items]
Disposal Group, Including Discontinued Operation, Proceeds							$ 173,800,000
Senior Credit Facilities \| Term Loan B Facility
Subsequent Event [Line Items]
Debt Instrument, Face Amount						$ 250,000,000
Subsequent Event
Subsequent Event [Line Items]
Disposal Group, Including Discontinued Operation, Proceeds				$ 60,000,000
Proceeds from Issuance of Long-term Debt	$ 194,500,000
Subsequent Event \| Revolving Credit Facility
Subsequent Event [Line Items]
Repayments of Short-term Debt	59,300,000
Subsequent Event \| Term Loan B Facility
Subsequent Event [Line Items]
Early Repayment of Senior Debt	$ 135,200,000
Subsequent Event \| Unsecured Debt \| Senior Unsecured 8.875% Notes
Subsequent Event [Line Items]
Debt Instrument, Face Amount			$ 200,000,000.0
Subsequent Event \| Second Term Loan Amendment \| Second Lien Debt \| Term Loan B Facility
Subsequent Event [Line Items]
Debt Covenants, New Debt Permitted					$ 150,000,000.0
Subsequent Event \| Second Term Loan Amendment \| Unsecured Debt \| Term Loan B Facility
Subsequent Event [Line Items]
Debt Covenants, New Debt Permitted					$ 250,000,000.0
Base Rate \| Senior Credit Facilities
Subsequent Event [Line Items]
Debt Instrument, Basis Spread on Variable Rate		4.25%
Base Rate \| Subsequent Event \| Term Loan B Facility
Subsequent Event [Line Items]
Debt Instrument, Basis Spread on Variable Rate		4.25%
Base Rate \| Subsequent Event \| Second Term Loan Amendment \| Term Loan B Facility
Subsequent Event [Line Items]
Debt Instrument, Basis Spread on Variable Rate		5.00%
Eurodollar \| Senior Credit Facilities
Subsequent Event [Line Items]
Debt Instrument, Basis Spread on Variable Rate		5.25%
Eurodollar \| Subsequent Event \| Term Loan B Facility
Subsequent Event [Line Items]
Debt Instrument, Basis Spread on Variable Rate		5.25%
Eurodollar \| Subsequent Event \| Second Term Loan Amendment \| Term Loan B Facility
Subsequent Event [Line Items]
Debt Instrument, Basis Spread on Variable Rate		6.00%

Schedule II (Details) - Allowance for Doubtful Accounts [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation Allowances and Reserves, Balance	$ 22,212	$ 22,728	$ 16,421
Valuation Allowances and Reserves, Deductions	(23,962)	(27,482)	(12,347)
Valuation Allowances and Reserves, Charged to Cost and Expense	20,963	26,966	18,654
Valuation Allowances and Reserves, Balance	$ 19,213	$ 22,212	$ 22,728